Previous
Previous Product Image

American Society of Clinical Oncology Virtual Education Program 2020

40 $
Next

Oakstone UCSF Controversies in Women’s Health 2018

20 $
Next Product Image

American Society of Clinical Oncology Virtual Scientific Program 2020

40 $

+ Include: 1326 videos + 417 pdfs, size: 574 GB

+ Target Audience: oncologist

Description

+ Include: 1326 videos + 417 pdfs, size: 574 GB

+ Target Audience: oncologist

+ Sample video: contact me for sample video

+ Topics:

[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol.mp4
12-chemokine gene expression score in breast cancer patients treated with neoadjuvant chemotherapy.mp4
17-year incidence trends of anal squamous cell carcinoma.mp4
4-miRNA signature combined with MGMT methylation status in glioblastoma.mp4
4R Program results in breast cancer the impact of 4R Care Delivery Model on timing and sequence of guideline.mp4
A comparison of patients’ and physicians’ expectations regarding precision oncology tests.mp4
A comprehensive analysis of the demographics and citation-based productivity of radiation oncologists practici.mp4
A Deep Dive Into Preoperative HER2 Biomarkers.mp4
A Deep Dive Into Preoperative HER2 Biomarkers.pdf
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody.mp4
A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer.mp4
A geriatric assessment (GA) intervention to reduce treatment toxicity in older patients with advanced cancer.pdf
A highly effective and practical desensitization regimen Results in comparable clinical outcomes for multiple myeloma patients.mp4
A Ib II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER).mp4
A Ib II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER).pdf
A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.mp4
A model comparing the value of broad next-gen sequencing (NGS)-based testing to single gene testing (SGT).pdf
A multicenter phase Ib II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine.mp4
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.mp4
A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.pdf
A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis.mp4
A multicenter study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis.pdf
A multicenter, randomized, controlled phase II study Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095).mp4
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+.mp4
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+.pdf
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data.mp4
A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer.mp4
A New Wave of Vaccine Strategies Making Progress.mp4
A New Wave of Vaccine Strategies Making Progress.pdf
A novel biosignature to assess residual risk in ductal carcinoma in situ (DCIS) patients after standard treatment.mp4
A pediatric and young adult phase I dose escalation study of BXQ-350 for solid and central nervous system tumors.mp4
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients.mp4
A pilot study of a wearable monitoring system as an adjunct to geriatric assessment in older adults with cancer.mp4
A pilot study of Bruton’s tyrosine kinase inhibitor ibrutinib alone and in combination with PD-1 inhibitor.mp4
A prospective analysis of chemotherapy-induced nausea and vomiting in gastrointestinal cancers.mp4
A prospective phase I trial of dendritic cell-based cryoimmunotherapy in metastatic castration-resistant prostate cancer.mp4
A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront.mp4
A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker.mp4
A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker.pdf
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.mp4
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients.mp4
A phase I combination study of GMCSF bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy.mp4
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive.mp4
A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate.mp4
A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination.mp4
A phase I II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune.mp4
A phase I II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab.mp4
A phase I II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.mp4
A phase I II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab.mp4
A phase I II study of REGN5093, a MET x MET bispecific antibody, in patients with MET-altered advanced.mp4
A phase I II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1).mp4
A phase I II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.mp4
A phase I II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors.mp4
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy.mp4
A phase I study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma.mp4
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36?.mp4
A phase I study of nanoliposomal irinotecan and 5-fluorouracil folinic acid in combination with interleukin-1-alpha.mp4
A phase I study of SHR6390, a cyclin-dependent kinase 4 6 inhibitor in patients with advanced breast cancer (ABC).mp4
A phase I trial targeting advanced or metastatic pancreatic cancer using a combination of standard chemotherapy.mp4
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1.mp4
A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1.pdf
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral.mp4
A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity.mp4
A phase Ia Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous.mp4
A phase Ib II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer.mp4
A phase Ib II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance.mp4
A phase Ib II study of olutasidenib in patients with relapsed refractory IDH1 mutant gliomas.mp4
A phase Ib II study of olutasidenib in patients with relapsed refractory IDH1 mutant gliomas.pdf
A phase Ib II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab.mp4
A phase Ib II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI).mp4
A phase Ib III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy.mp4
A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten.mp4
A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+).mp4
A phase Ib study of endogenous SLC45A2-specific cytotoxic T cells for the treatment of patients with metastatic uveal melanoma.mp4
A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).mp4
A phase Ib study of TQ-B2450 plus anlotinib in patients with advanced solid tumor.mp4
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined.mp4
A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).mp4
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P).mp4
A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736).mp4
A phase II double-blind, randomized clinical trial assessing the tolerability of two different ratios of cannabis in patients.mp4
A phase II III study of JZP-458 in patients with acute lymphoblastic leukemia (ALL) lymphoblastic lymphoma (LBL).mp4
A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.pdf
A phase II open-label, multicenter, study to evaluate the efficacy and safety of rivoceranib in subjects with recurrent.mp4
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination.mp4
A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma.mp4
A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.mp4
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination.mp4
A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced.mp4
A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced.pdf
A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics.mp4
A phase II study of osimertinib for patients with radiotherapy-na‹ve CNS metastasis of non-small cell lung cancer.mp4
A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent.mp4
A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11).mp4
A phase II study on the efficacy and toxicity of cabozantinib in recurrent metastatic salivary gland cancer patients.mp4
A phase II study to evaluate the need for two doses of nivolumab + ipilimumab combination (combo) immunotherapy.mp4
A phase II study to evaluate the need for two doses of nivolumab + ipilimumab combination (combo) immunotherapy.pdf
A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer.mp4
A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases.mp4
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men.mp4
A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic.mp4
A phase II trial of preoperative FOLFIRINOX followed by gemcitabine-based chemoradiotherapy in patients.mp4
A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.mp4
A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma.pdf
A phase II, multicenter study of encorafenib binimetinib followed by a rational triple-combination after progression in patients.mp4
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing.mp4
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing.pdf
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO).mp4
A phase III randomized trial of pleurectomy decortication plus chemotherapy with or without adjuvant hemithoracic.mp4
A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue.mp4
A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil) to reduce cancer-related fatigue.pdf
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based.mp4
A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based.pdf
A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C).mp4
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer.mp4
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic.mp4
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+ HER2- primary.mp4
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts).mp4
A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone.mp4
A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients.mp4
A randomized controlled trial (RCT) testing a mobile application (app) to identify cancer treatment-related financial assistance.mp4
A randomized controlled trial of a self-administered, online decision-aid (‘Navya Patient Preference Tool’).mp4
A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer.mp4
A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer.pdf
A randomized phase I IIa study to evaluate the safety and efficacy of SNK01.mp4
A randomized phase II feasibility study of individualized stereotactic body radiation therapy (SBRT) versus transarterial.mp4
A randomized phase II III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver.mp4
A randomized phase II III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver.pdf
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.mp4
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.pdf
A randomized phase II study of gemcitabine (G) alone or with pazopanib (P) in refractory soft tissue sarcoma (STS).mp4
A randomized phase II trial of secondary cytoreductive surgery (SCS) + – carboplatin hyperthermic intraperitoneal.mp4
A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer SOC1 SGOG-OV2.mp4
A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer SOC1 SGOG-OV2.pdf
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women.mp4
A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women.pdf
A randomized trial of a palliative care intervention for patients on phase I studies.mp4
A randomized trial of a palliative care intervention for patients on phase I studies.pdf
A randomized, double-blind, phase II clinical trial of GI-6301 (yeast-brachyury vaccine) versus placebo in combination.mp4
A sensitive and quantitative multimodal blood test for the detection of colorectal adenomas and cancer.mp4
A signal-seeking trial of olaparib and durvalumab in homologous repair-deficient tumors.mp4
A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line.mp4
A single-arm multicenter phase II trial of doxorubicin (Doxo) in combination with trabectedin (Trab) given as first-line.pdf
A single-institution and commercial laboratory database analysis of BRIP1-associated cancer risks.mp4
A survey of cannabis use for symptom palliation in breast cancer patients by age and stage.mp4
Abbreviated geriatric assessment (GA) in new oncology patients and its association with early death.mp4
Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed refractory (R R).mp4
Acalabrutinib in treatment-na‹ve chronic lymphocytic leukemia Mature results from phase II study demonstrating.mp4
Accelerating New Agents in Slow-Growing Lymphomas.mp4
Accelerating New Agents in Slow-Growing Lymphomas.pdf
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection.mp4
Accuracy of 68Ga-PSMA-11 for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection.pdf
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination.mp4
Activity and safety of larotrectinib in adult patients with TRK fusion cancer An expanded data set.mp4
Activity of front-line window therapy with temozolomide plus irinotecan in patients with primary multifocal Ewing sarcoma.mp4
Activity of front-line window therapy with temozolomide plus irinotecan in patients with primary multifocal Ewing sarcoma.pdf
Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cance.mp4
ACUFOCIN Randomized clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy.mp4
ACUFOCIN Randomized clinical trial of ACUpuncture plus standard care versus standard care alone FOr Chemotherapy.pdf
ADAPTcycle Adjuvant dynamic marker-adjusted personalized therapy (ADAPT) comparing endocrine therapy plus.mp4
Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese).mp4
Adding to Chemotherapy in Mesothelioma.mp4
Adding to Chemotherapy in Mesothelioma.pdf
Adjuvant and Neoadjuvant Therapies in 2020.mp4
Adjuvant and Neoadjuvant Therapies in 2020.pdf
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.mp4
Adjuvant lenvatinib in combination with TACE for hepatocellular carcinoma patients with high risk of postoperative relapse (LANCE).mp4
Adjuvant Neoadjuvant Approaches What Works and What Doesn’t.mp4
Adjuvant Neoadjuvant Approaches What Works and What Doesn’t.pdf
Adjuvant or neoadjuvant for nasopharynx That is the question.mp4
Adjuvant Studies in Rare Populations.mp4
Adjuvant Studies in Rare Populations.pdf
Adjuvant Therapy When Did It Get So Complex.mp4
Adjuvant Therapy When Did It Get So Complex.pdf
Adoption of opportunistic salpingectomy for ovarian cancer prevention Results from a nationwide sample.mp4
Adoptive T-Cell Therapies for Solid Tumors Square Peg, Round Hole.mp4
Adoptive T-Cell Therapies for Solid Tumors Square Peg, Round Hole.pdf
Advanced Prostate Cancer Putting Survival Into Perspective.mp4
Advanced Prostate Cancer Putting Survival Into Perspective.pdf
Advances in CAR-T From Hematologic to Solid Tumors.mp4
Advances in Checkpoint Inhibition Through Toxicity and Drug Development Insights.mp4
Advances in Checkpoint Inhibition Through Toxicity and Drug Development Insights.pdf
Affordable Care Act Medicaid expansion does not reduce guideline concordant cancer care disparities in vulnerable populations.mp4
AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment.mp4
Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular.mp4
ALL From the Tried and True to the Targeted and New.mp4
Alliance A071401 Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.mp4
Alliance A071401 Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.pdf
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+).mp4
Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+).pdf
ALTERNATE Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive.mp4
ALTERNATE Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive.pdf
Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions.mp4
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins).mp4
Amyloidosis Don’t Suffer ‘The Runaways’.mp4
Amyloidosis Don’t Suffer ‘The Runaways’.pdf
An automated EHR-based tool for identification of patients (pts) with metastatic disease to facilitate clinical trial.mp4
An exploratory study of sorafenib plus toripalimab for unresectable hepatocellular carcinoma with portal vein tumor thrombus.mp4
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440).mp4
An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors.mp4
Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.mp4
Analysis of mutation detection of POLD1 pole in pan-cancer.mp4
Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients.mp4
Analytical validation of digital cytometry (iSort) for leukocyte enumeration using stored blood.mp4
Ancestry-specific gene expression profiles in TNBC tumors.pdf
Androgen Deprivation Too Little, Too Much, or Just Right.mp4
Androgen Deprivation Too Little, Too Much, or Just Right.pdf
Annual trends in opioid prescribing for patients (Pts) with metastatic non-small cell lung cancer (mNSCLC).mp4
Anti-CTLA-4 probody BMS-986249 alone or in combination with nivolumab in patients with advanced cancers.mp4
Antiemetic prophylaxis with NEPA Final results of the German AKYPRO study.mp4
Anti-PD-1 in Less Common Skin Cancers.mp4
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma.mp4
Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma.pdf
Application of machine learning algorithms for the diagnosis of primary brain tumors.mp4
Are symptoms distinguishable in ovarian cancer A nested case control study of insurance claims.mp4
Are We Able to Move Beyond PD-L1.mp4
Are We Able to Move Beyond PD-L1.pdf
ARISTOTLE A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation.mp4
ASPEN Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstr”m macroglobulinemia (WM).mp4
ASPEN Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenstr”m macroglobulinemia (WM).pdf
Assessing impact of inpatient rotations on resident interest in hematology-oncology.mp4
Assessing MRD in Multiple Myeloma Leave ‘No Doubt’.mp4
Assessing MRD in Multiple Myeloma Leave ‘No Doubt’.pdf
Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.mp4
Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy.mp4
Assessment of FcgRIIIA single nucleotide polymorphisms (SNPs) on the efficacy of IgG1 monoclonal antibodies (mAbs).mp4
Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi).mp4
Association between immune and tumor gene signatures with response or resistance to tislelizumab monotherapy.mp4
Association between Medicaid expansion status and metastatic disease at diagnosis in patients with melanoma.mp4
Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts).mp4
Association of chronotype and pain at baseline in ovarian cancer survivors participating in a lifestyle intervention (NRG GOG 0225).mp4
Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC).mp4
Association of elevated red cell distribution width and overall survival in multiple myeloma.mp4
Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.mp4
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint.mp4
Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint.pdf
Association of lymphocyte to monocyte ratio with clinical response and survival in patients with relapsed.mp4
Association of medical comorbidities and cardiovascular disease with toxicity and survival in patients.mp4
Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101.mp4
Association of sarcopenia with higher toxicity and poor prognosis in nasopharyngeal carcinoma.mp4
Associations between psoas muscle area (PMA) and density (PMD) with phase I oncology clinical trial outcomes.mp4
Associations between psoas muscle area (PMA) and density (PMD) with phase I oncology clinical trial outcomes.pdf
AST-008 A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC).mp4
Atezolizumab (atezo) therapy for locally advanced metastatic urinary tract carcinoma (mUTC) in patients (pts).mp4
Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R R DLBCL).mp4
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).mp4
ATM mutation carriers and family history of pancreatic cancer.mp4
Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition.mp4
Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition.pdf
Autoantibodies in Response and Toxicity.mp4
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission.mp4
Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy.mp4
Avelumab in patients with gestational trophoblastic tumors resistant to monochemotherapy.pdf
AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor Safety and biomarker results of a phase I.mp4
Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma Long-term efficacy and safety from a phase Ib study.mp4
Balancing Access, Value, and Quality of Care!.mp4
Balancing Access, Value, and Quality of Care!.pdf
Balancing Risk and Benefit in Metastatic Colorectal Cancer.mp4
BARCODE 1 A pilot study investigating the use of genetic profiling to identify men in the general population.mp4
BARCODE 1 A pilot study investigating the use of genetic profiling to identify men in the general population.pdf
Barriers to prescribing targeted therapies for NSCLC patients with highly actionable gene variants in the VA.mp4
Basal subtype and clinical estrogen receptor status of genomically basal breast tumors in.mp4
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate.mp4
Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate.pdf
Battle of the Clones Establishing the Leukemia Roadmap.mp4
Benefits of an early mobility program for hospitalized cancer patients A pilot study.mp4
Benefits of an early mobility program for hospitalized cancer patients A pilot study.pdf
BET inhibitor molibresib for the treatment of advanced solid tumors Final results from an open-label phase I II study.mp4
Better and Safer Surgery for Gastroesophageal Cancer.mp4
Beyond PACIFIC Balancing Benefit and Risk.mp4
Beyond Sedlis A novel, histology-based nomogram for predicting recurrence risk and need for adjuvant radiation.mp4
Big Changes in the Care of Metastatic Disease.mp4
Big Changes in the Care of Metastatic Disease.pdf
Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S).mp4
Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S).pdf
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+ HER2- metastatic.mp4
Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic.mp4
Biomarker data from KATHERINE A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H).mp4
Biomarker data from KATHERINE A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H).pdf
Biomarkers of Single Agent Versus Combination Checkpoint Inhibitors in Advanced Renal Cell Carcinoma.mp4
Biomarkers of Single Agent Versus Combination Checkpoint Inhibitors in Advanced Renal Cell Carcinoma.pdf
Bispecifics A ‘Two for One’ Strategy.mp4
Bispecifics A ‘Two for One’ Strategy.pdf
Bortezomib induction prior to autologous hematopoietic cell transplantation (AHCT) for newly diagnosed light.mp4
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure.mp4
Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure.pdf
Bosutinib in patients with chronic phase chronic myeloid leukemia intolerant to prior tyrosine kinase inhibitors.mp4
Brain Tumor Microenvironment Exploring New Territory.mp4
BRCA testing concordance with national guidelines for patients with breast cancer in community cancer programs.mp4
Breaking Bad Evaluating Efficacy of Old and New Drugs on Symptom Management.mp4
Breaking Bad Evaluating Efficacy of Old and New Drugs on Symptom Management.pdf
Breast Cancer – Local Regional Adjuvant.mp4
Breast Cancer – Local Regional Adjuvant.pdf
Breast Cancer – Metastatic.mp4
Breast Cancer – Metastatic.pdf
Breast cancer events in women with atypical ductal hyperplasia who do not undergo surgical excision.mp4
Breast cancer grade and clinical benefit in patients with advanced breast cancer treated with an engineered.mp4
Breast Cancer Index (BCI) predicts benefit of two-and-a-half versus five years of extended endocrine therapy.mp4
Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients.mp4
BT5528-100 phase I II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients.mp4
B-TREUH A single-arm phase II pilot study of euthyroid hypothyroxinemia in metastatic breast carcinoma.mp4
Building a New Model Innovations in Educating the Trainee and Community.mp4
Burnout among oncology physician assistants (PAs) from 2015 to 2019.mp4
Burnout Is Universal It’s Not Just a Problem for American Physicians.mp4
CA209-9JC A phase II study of first-line nivolumab (NIVO) in patients (pts) with locally advanced or metastatic.mp4
Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI).mp4
Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated.mp4
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer.mp4
Cabozantinib in combination with atezolizumab in urothelial carcinoma previously treated with platinum-containing chemotherapy.mp4
Can Antibody-Based Therapy Replace Chemotherapy in Hodgkin Lymphoma.mp4
Can FIT rule out colorectal cancer in symptomatic patients Diagnostic test accuracy results from 9,822 patients.mp4
Can sentinel node biopsy after neoadjuvant systemic chemotherapy (NAC) be safely omitted in selected patient.mp4
Cancer of Unknown Primary How Did We Get Here.mp4
Cancer of Unknown Primary How Did We Get Here.pdf
Cancer Prevention, Risk Reduction, and Genetics.mp4
Cancer Prevention, Risk Reduction, and Genetics.pdf
CANOPY-A A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab.mp4
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC).mp4
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC).pdf
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC).mp4
Carboplatin versus cisplatin for the treatment of extensive-stage small cell lung cancer (SCLC) A National VA Database analysis.mp4
CARD Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC).mp4
Cardiomyopathy risk among childhood cancer survivors of African ancestry and its molecular mechanisms.mp4
Cardiomyopathy risk among childhood cancer survivors of African ancestry and its molecular mechanisms.pdf
Care Delivery and Regulatory Policy.mp4
Care Delivery and Regulatory Policy.pdf
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd).mp4
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd).pdf
Caring for transgender cancer patients Shortcomings of medical education.mp4
CARS and BITES in the Fight.mp4
Castleman disease spectrum.mp4
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (75 years) with acute myeloid leukemia (AML).mp4
CCTG BR.34 A randomized trial of durvalumab and tremelimumab + – platinum-based chemotherapy in patients.mp4
CCTG BR.34 A randomized trial of durvalumab and tremelimumab + – platinum-based chemotherapy in patients.pdf
CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).mp4
CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL).pdf
CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease.mp4
Cediranib in combination with olaparib in patients without a germline BRCA1 2 mutation with recurrent.mp4
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer.mp4
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer.pdf
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape.mp4
Cell-Free DNA in the Management of Glioma CSF Versus Blood.mp4
Cell-Free DNA in the Management of Glioma CSF Versus Blood.pdf
Central Nervous System Tumors.mp4
Central Nervous System Tumors.pdf
Cetuximab irinotecan 5-FU + -oxaliplatin or FOLFOXIRI + – bevacizumab in patients with colorectal cancer.mp4
CIFeR A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors.mp4
Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration.mp4
Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS).mp4
Circulating tumor DNA (ctDNA) dynamics associate with treatment response and radiological progression-free survival (rPFS).pdf
Circulating tumor DNA dynamics to predict cancer recurrence metastasis in Chinese pathologic stage I lung adenocarcinoma.mp4
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients.mp4
Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell.mp4
Clarifying the Role of IMID Combinations in Peripheral T-cell Lymphoma and Diffuse Large B-cell Lymphoma.mp4
Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib.mp4
Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+ HER2-low.mp4
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.mp4
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.pdf
Clinical and genetic risk factors for radiation-associated ototoxicity A report from the childhood cancer survivor.mp4
Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers.mp4
Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared.mp4
Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC).mp4
Clinical impact of COVID-19 on patients with cancer Data from the COVID-19 and Cancer Consortium (CCC19).mp4
Clinical impact of COVID-19 on patients with cancer Data from the COVID-19 and Cancer Consortium (CCC19).pdf
Clinical impact of targetable gene alterations on therapeutic outcomes in stage II III locally advanced non-small cell lung cancer patients.mp4
Clinical outcome of patients experiencing central nervous system progression on first-line pertuzumab.mp4
Clinical outcomes with early-elective discontinuation of PD-1 inhibitors (PDi) at one year in patients (pts) with metastatic melanoma (MM).mp4
Clinical performance of a comprehensive novel liquid biopsy test for identifying non-small cell lung cancer (NSCLC) patients.mp4
Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant.mp4
Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC).mp4
Clinicopathologic and molecular profile of Philadelphia like ALL in Hispanic population of Central Valley California.mp4
Clinicopathologic characteristics and immunotherapy outcomes in SMARCA4-mutant (mut) non-small cell lung cancer (NSCLC).mp4
Cobimetinib plus gemcitabine is an active combination in KRAS G12R-mutated in previously chemotherapy-treated.mp4
CodeBreak 100 Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer.mp4
CodeBreak 100 Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors.mp4
Colorectal cancer under the age of 50 years in U.S. Department of Veterans Affairs Is there a role of early screening.mp4
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).mp4
Coming to a Microenvironment Near You.mp4
Coming to a Microenvironment Near You.pdf
Common Problems and Rare Breakthroughs.mp4
Common Problems and Rare Breakthroughs.pdf
Comparative analysis of characteristics, survival trends, and associated malignancies of B-cell and T-cell prolymphocytic leukemia.mp4
Comparative effectiveness of second-line (2L) single-agent atezolizumab (A), nivolumab (N), and pembrolizumab (P).mp4
Comparative study of therapy-related (tALL) and de novo adult acute lymphoblastic leukemia (dnALL).mp4
Comparing and assessing the reported penetrance of cancer susceptibility genes for breast cancer.mp4
Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403.mp4
Comparison of different systemic therapeutic regimes in resectable high-risk soft tissue sarcoma.mp4
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients.mp4
Comparison of recurrence patterns after surgery and radiation therapy with 68Ga-PSMA-11 PET CT in nonmetastatic.mp4
Comparison of two chemotherapy regimens in Ewing sarcoma (ES) Overall and subgroup results of the Euro Ewing 2012.pdf
Complete human papillomavirus vaccination coverage over a 13-year period in a large population of privately.mp4
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150.mp4
Completing the Circle for EGFR-Directed Therapies.mp4
Composite grading algorithm for National Cancer Institute’s PRO-CTCAE.mp4
Comprehensive analysis of HER2 status through genomic, transcription, and translation among 5,305 patients.mp4
Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC).mp4
Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS).mp4
Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS).pdf
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts).mp4
Computational discovery of non-mutational tumor-restricted antigens reveals evidence of immunoediting.mp4
Concordance study of treatment guidance from an online patient assistance algorithm (OCPAP) and treatment.mp4
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).mp4
Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).pdf
Consensus molecular subtype (CMS) as a novel integral biomarker in colorectal cancer.mp4
Consensus molecular subtypes (CMS) as a marker for treatment and disease biology in metastatic colorectal cancer (CRC).mp4
Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC).mp4
Continuing the PARP Journey.mp4
Continuing the PARP Journey.pdf
Continuing treatment Is it worth it.mp4
Continuing treatment Is it worth it.pdf
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.mp4
Correlation between overall response rate and progression-free survival overall survival in comparative trials.mp4
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.mp4
Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.mp4
Correlation of pathogenic POLE mutations with clinical benefit to immune checkpoint inhibitor therapy.pdf
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving.mp4
CT-based radiomic classifier of primary renal tumors to distinguish between metastatic and non-metastatic disease.mp4
CTEP 9557 A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF.mp4
CTONG1104 Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation.mp4
CTONG1104 Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation.pdf
CULMINATE A phase II study of cusatuzumab + azacitidine in patients with newly diagnosed AML, ineligible for intensive chemotherapy.mp4
CX-2009, a CD166-directed probody drug conjugate (PDC) Results from the first-in-human study in patients (Pts).mp4
CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor) Results from a first-in-human study.mp4
CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor) Results from a first-in-human study.pdf
CYAD-101 An innovative non-gene edited allogeneic CAR-T for solid tumor cancer therapy.mp4
Change in cardiac function with CPX-351 in relapsed pediatric AML A Children’s Oncology Group (COG) report from AAML1421.mp4
Changes in cancer mortality rates after the adoption of the Affordable Care Act.mp4
Changes in cancer mortality rates after the adoption of the Affordable Care Act.pdf
Characteristics and outcomes of real-world (RW) patients (pts) with microsatellite instability-high (MSI-H) solid tumors.mp4
Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR).mp4
Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR).pdf
Characterization of clonal hematopoiesis of indeterminate potential mutations from germline whole exome sequencing data.mp4
Characterization of NRG1 gene fusion events in solid tumors.mp4
Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).mp4
Characterization of patients with multiple primary tumors.mp4
Characterization of patients with multiple primary tumors.pdf
Characterizing Long-Term Outcomes in Metastatic Melanoma in 2020.mp4
CheckMate 067 Long-term outcomes in patients with mucosal melanoma.mp4
Checkmate 77T A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed.mp4
Checkpoint inhibitor treatment-related cutaneous adverse events in skin of color patients at Memorial Sloan Kettering Cancer Center.mp4
Chemo-immunotherapy in Small Cell Lung Cancer Many Questions Remain.mp4
Chemo-immunotherapy in Small Cell Lung Cancer Many Questions Remain.pdf
Chemotherapy (CT) de-escalation using an FDG-PET CT (F-PET) and pathological response-adapted strategy.mp4
Chemotherapy (CT) de-escalation using an FDG-PET CT (F-PET) and pathological response-adapted strategy.pdf
Chemotherapy remote care monitoring program (CRCMP) Integration of an SMS text patient-reported outcome (PRO).mp4
Chemotherapy remote care monitoring program (CRCMP) Integration of an SMS text patient-reported outcome (PRO).pdf
Chew on This Reintroduction of Induction, in Oral Cavity, No Less.mp4
Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma.mp4
Dabrafenib + trametinib combination therapy in pediatric patients with BRAF V600-mutant low-grade glioma.pdf
DaroACT Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients.mp4
Deciphering Clonal Hematopoiesis Not a CHIP Shot.mp4
Deep learning for improved prediction of late-onset cardiomyopathy among childhood cancer survivors.mp4
Deep learning to identify high-risk smokers for lung cancer screening from chest radiographs.mp4
De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+ HER2+.mp4
Defining patient-elicited concepts unique to adolescents and young adults with cancer.mp4
Defining the mutational landscape of 3,217 primary breast cancer transcriptomes through large-scale RNA-seq.mp4
Delivery of cancer survivorship education to community health care professionals.mp4
Depression, anxiety, and patterns of mental health care among men with prostate cancer on androgen deprivation therapy (ADT).mp4
Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma.mp4
Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma.pdf
Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients.mp4
Detection of actionable gene mutations in breast cancer by amplicon-based next-generation sequencing liquid.mp4
Developing South Asia’s first structured head and neck surgery multicenter fellowship initiative.mp4
Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.mp4
Development and validation of a pediatric disease risk index for allogeneic hematopoietic cell transplantation.pdf
Development and validation of an early death risk score for older patients treated with chemotherapy for cancer.mp4
Development and validation of natural language processing (NLP) algorithm for detection of distant versus local.mp4
Development of drug resistance in colon cancer patients following chemotherapy, a contributing factor in the failure.mp4
Developmental Therapeutics-Immunotherapy.mp4
Developmental Therapeutics-Immunotherapy.pdf
Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology.mp4
Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology.pdf
Dexrazoxane and heart function among long-term childhood cancer survivors A Children’s Oncology Group study.mp4
Dexrazoxane and heart function among long-term childhood cancer survivors A Children’s Oncology Group study.pdf
Diagnosis of leptomeningeal metastasis (LM) through identification of circulating tumor cells (CTCs) in cerebrospinal fluid (CSF).mp4
Dietary advanced glycation end products (AGEs) and breast cancer mortality in the women’s health initiative (WHI).mp4
Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary.mp4
Different response to ALK inhibitors in EML4-ALK positive mediastinal cancer of unknown primary.pdf
Discovery of a novel shared tumor antigen in human lung cancer.mp4
Discussion – Redefining Cancer of Unknown Primary Is Genomics the Answer.mp4
Discussion of LBA1.mp4
Discussion of LBA1.pdf
Discussion of LBA2.mp4
Discussion of LBA2.pdf
Discussion of LBA3.mp4
Discussion of LBA3.pdf
Discussion of LBA4.mp4
Discussion of LBA4.pdf
Discussion of LBA5.mp4
Discussion of LBA5.pdf
Dissecting Out Improved Outcomes.mp4
Dissecting Out Improved Outcomes.pdf
Dissecting outcomes of patients (pts) with ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive.mp4
Diversity in Oncology Towards Evidence-Based Transformation.mp4
Does sinonasal cancer survival differ based on human papillomavirus status.mp4
Does the Patient Know Best.mp4
Does the Patient Know Best.pdf
Dollars and Sense Reducing Physical and Financial Toxicity.mp4
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma An open-label, randomized.mp4
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma An open-label, randomized.pdf
Dose and volume de-escalation for HPV-associated oropharyngeal cancer Long-term follow-up of the OPTIMA trial.mp4
DREAMM-2 Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.mp4
DREAMM-2 Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed refractory multiple myeloma (RRMM) and renal impairment.mp4
DREAMM-5 platform trial Belantamab mafodotin in combination with novel agents in patients with relapsed.mp4
DREAMM-6 Safety and tolerability of belantamab mafodotin in combination with bortezomib.mp4
DREAMM-6 Safety and tolerability of belantamab mafodotin in combination with bortezomib.pdf
DREAMM-9 Phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly.mp4
Driving quality improvement How clinical decision support can facilitate compliance with evidence-based pathways.mp4
Drugs Old and New for Metastatic Breast Cancer.pdf
DUO-E GOG-3041 ENGOT-EN10 a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac).mp4
Durvalumab ñ tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC).mp4
Durvalumab ñ tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC).pdf
Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable.mp4
Durvalumab and tremelimumab in combination with FOLFOX in patients with RAS-mutated, microsatellite-stable.pdf
DUTRENEO Trial A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy.mp4
DUTRENEO Trial A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy.pdf
Early ctDNA response assessment for prediction of platinum sensitivity in small cell lung cancer.mp4
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.mp4
Early discontinuation to adjuvant endocrine therapy in the ECOG-ACRIN TAILORx Trial.pdf
Early pulmonary function changes associated with brigatinib initiation.mp4
Early results of TROPHY-U-01 Cohort 2 Sacituzumab govitecan (SG) in platinum-ineligible patients (pts).mp4
Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj).mp4
Early-stage breast cancer (BC) patients Factors associated with aromatase inhibitor-induced musculoskeletal.mp4
ECOG-ACRIN tomosynthesis mammographic imaging screening trial (EA1151).mp4
Effect of a supportive medicine program for cancer patients on patient connectivity to care and health care utilization.mp4
Effect of anlotinib in advanced small cell lung cancer (SCLC) patients relapsed within three months after second-line treatment.mp4
Effect of early blood counts on overall survival (OS) following glasdegib + LDAC in newly diagnosed AML.mp4
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy.mp4
Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy.pdf
Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood.mp4
Effect of integrating machine learning mortality estimates with behavioral nudges to increase serious illness conversions.mp4
Effect of integrating machine learning mortality estimates with behavioral nudges to increase serious illness conversions.pdf
Effect of linguistic acculturation on self-efficacy and anxiety in caregivers of Latina breast cancer survivors.mp4
Effect of live education targeted to genetic counselors on knowledge and competence.mp4
Effect of participation in the annual Immuno-oncology Young Investigators’ Forum (IOYIF) on the competency.mp4
Effect of pembrolizumab (pembro) on hepatitis B viral (HBV) load and aminotransferase (ALT) levels in patients (pts).mp4
Effect of performance status on survival with pembrolizumab monotherapy in advanced non-small cell lung cancer (NSCLC).mp4
Effect of shorter time to treatment on survival in rural patients with breast cancer.mp4
Effect of video-based patient education on pancreatic cancer knowledge and behavior.mp4
Effect on response to neoadjuvant chemotherapy in high-grade serous ovarian cancer by inhibiting the GAS6 AXL pathway.mp4
Effectiveness of adjuvant FOLFOX versus 5FU for colon cancer treatment in community oncology practice.mp4
Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors.mp4
Effects of electroacupuncture and auricular acupuncture for chronic pain in cancer survivors.pdf
Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients.mp4
Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia.mp4
Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia.pdf
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ).mp4
Efficacy and safety of ABP 798 compared with rituximab Results from the comparative clinical study in patients with non-Hodgkin’s.mp4
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg m2 and once-weekly at 70 mg m2.mp4
Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors An updated integrated analysis.mp4
Efficacy and safety of olaparib according to age in BRCA-1 2 mutated patients with recurrent platinum-sensitive ovarian cancer.mp4
Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).mp4
Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous.mp4
Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous.pdf
Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma.pdf
Efficacy of ear acupuncture on sleep quality in breast cancer survivors A randomized controlled trial.mp4
Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).mp4
Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC).mp4
Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.mp4
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts).mp4
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts).pdf
Emerging Biomarkers of Checkpoint Inhibitors-Based Combinations in Urothelial Cancer.mp4
Emerging Biomarkers of Checkpoint Inhibitors-Based Combinations in Urothelial Cancer.pdf
Emerging Immunotherapy for Glioma What Justifies Phase III Testing.mp4
Emerging Immunotherapy for Glioma What Justifies Phase III Testing.pdf
Emerging Unmet Needs in RCC An Ideal Sequential Strategy and the Post-immunotherapy Space.mp4
Emerging Unmet Needs in RCC An Ideal Sequential Strategy and the Post-immunotherapy Space.pdf
Emotional distress, stress, and cardiovascular health in adult survivors of childhood cancer.mp4
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer.mp4
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer.pdf
Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer.mp4
Endometrial Cancer and SCCOHT Small Studies, Big Impact.mp4
Endometrial Cancer and SCCOHT Small Studies, Big Impact.pdf
Ensuring Cancer Research Progress During a Global Pandemic.mp4
Ensuring Cancer Research Progress During a Global Pandemic.pdf
ENGOT-EN6 NSGO-RUBY A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel.mp4
ENGOT-OV44 FIRST study a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based.mp4
Enhanced coping and self-efficacy in caregivers of hematopoietic stem cell transplant (HCT) recipients.mp4
Enhanced efficacy of anti-VEGFR2 taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts).mp4
Enhancing cancer literacy among Appalachian Kentucky middle and high school students.mp4
Enhancing Decision-Making in Advanced Breast Cancer.mp4
Epcoritamab (GEN3013; DuoBody-CD3xCD20) to induce complete response in patients with relapsed.mp4
Epigenetic control of breast cancer susceptibility.mp4
Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection.mp4
Equivalence randomized trial comparing treatment based on sentinel node biopsy versus neck dissection.pdf
ERBB2 amplifications and mutations in 109 advanced breast cancer patients by next-generation sequencing.mp4
ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC) Long-term outcomes in BLC2001.mp4
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse.mp4
ESPAC-4 A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination.mp4
ESPAC-5F Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared.mp4
ESPAC-5F Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared.pdf
Establishing analytical and clinical similarity between HD201 and herceptin.mp4
Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene.mp4
Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL).mp4
Etanercept with extracorporeal photopheresis (ECP) for steroid-refractory acute graft versus host disease following.mp4
EV-202 A phase II study of enfortumab vedotin in patients with select previously treated locally advanced.mp4
Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts).mp4
Evaluation of a computational decision support system for molecularly targeted treatment planning by the clinical.mp4
Evaluation of an individualized starting-dose of niraparib in the PRIMA ENGOT-OV26 GOG-3012 study.mp4
Evaluation of blood TMB (bTMB) in KEYNOTE-189 Pembrolizumab (pembro) plus chemotherapy (chemo).mp4
Evaluation of blood TMB (bTMB) in KEYNOTE-189 Pembrolizumab (pembro) plus chemotherapy (chemo).pdf
Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO).mp4
Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit.mp4
Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).mp4
Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine.mp4
Evaluation of spatiotemporal heterogeneity of PDL1 expression in gastroesophageal adenocarcinoma (GEA) at baseline.mp4
Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA).mp4
Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head.mp4
Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head.pdf
Evaluation of the incidence of pneumonitis in United States veterans with non-small cell lung cancer receiving.mp4
Even the Gold Standard Can be Refined The Strength and Limitations of Randomized Clinical Trials.mp4
Even the Gold Standard Can be Refined The Strength and Limitations of Randomized Clinical Trials.pdf
Everything old is new again Modulation and delivery of topoisomerase I mediated DNA damage.mp4
Evidence of intratumoral localization, activation, and immunomodulatory effect of CX-072, a probody therapeutic.mp4
Evolving development of PD-1 therapy Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.mp4
Evolving risk of therapy-related myelodysplastic syndromes and acute myeloid leukemia (tMDS AML) following modern cancer therapies.mp4
Exome scale liquid biopsy characterization of putative neoantigens and genomic biomarkers pre- and post anti-PD-1.mp4
Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing.mp4
Exosomal circular RNAs derived from serum Promising biomarkers for therapeutic targets and prognosis of.mp4
Expanding criteria for prognostic stage IA disease in HR+ breast cancer.mp4
Expanding Immunotherapy and Molecular Subtyping Into New Settings.mp4
Expanding Immunotherapy and Molecular Subtyping Into New Settings.pdf
Expanding the Reach of MET-Directed Therapy.mp4
Expanding the Reach of MET-Directed Therapy.pdf
Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy.mp4
Expression of the senescence biomarker p16INK4a among childhood, adolescent, and young adult cancer survivors.mp4
External validation of two predictive scores of chemotherapy toxicities among older patients with solid cancer.mp4
Extrachromosomal DNA (ecDNA) carrying amplified oncogenes as a biomarker for insensitivity to checkpoint.mp4
Factors associated with axillary conversion after neoadjuvant chemotherapy in initially node positive breast cancer.mp4
Fatigue in long-term survivors with ovarian cancer Results of Expression VI – Carolin meets HANNA.mp4
FDA analysis Impact of BMI on efficacy outcomes in multiple myeloma trials.mp4
Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin.mp4
Feasibility of olanzapine at reduced dose in highly emetogenic chemotherapy.mp4
Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.mp4
Feeling the Burn Exposing Disparities in Radiation Oncology as a Benchmark for Change.mp4
Final analysis of KEYNOTE-189 Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro).mp4
Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).mp4
Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).pdf
Final overall survival (OS) from PROSPER A phase III, randomized, double-blind, placebo (PBO).mp4
Final overall survival (OS) from PROSPER A phase III, randomized, double-blind, placebo (PBO).pdf
Final overall survival (OS) results from SOLO2 ENGOT-ov21 A phase III trial assessing maintenance olaparib in patients (pts).mp4
Final overall survival (OS) results from SOLO2 ENGOT-ov21 A phase III trial assessing maintenance olaparib in patients (pts).pdf
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.mp4
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.pdf
Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.mp4
Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts).mp4
Financial toxicity and patient-reported outcomes over time A longitudinal study of women with recurrent ovarian cancer.mp4
Finding Our Blind Spot Innovation in LGBTQ+ Medical Education.mp4
Finding Our Blind Spot Innovation in LGBTQ+ Medical Education.pdf
First safety and efficacy results of PRADO A phase II study of personalized response-driven surgery and adjuvant.mp4
First safety and efficacy results of PRADO A phase II study of personalized response-driven surgery and adjuvant.pdf
First-in-human data of ALLO-501 and ALLO-647 in relapsed refractory large B-cell or follicular lymphoma.mp4
First-in-human data of ALLO-501 and ALLO-647 in relapsed refractory large B-cell or follicular lymphoma.pdf
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts).mp4
First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients.mp4
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts).mp4
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts).pdf
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2 Bcl-xL inhibitor, demonstrated advantages.mp4
First-line biological agents plus chemotherapy in elderly patients with metastatic colorectal cancer A retrospective pooled analysis.mp4
First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN) Impact of brain metastases.mp4
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients.mp4
First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients.pdf
First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC).mp4
First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm.mp4
First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm.pdf
Fishing for Complements Improving Symptoms Through Integrative Oncology.mp4
Fishing for Complements Improving Symptoms Through Integrative Oncology.pdf
Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk secondary AML.mp4
Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia.mp4
FOENIX-CCA2 A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic.mp4
FOENIX-CCA2 A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic.pdf
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC) A multicenter real-life study.mp4
FOLFOXIRI bevacizumab (bev) versus doublets bev as initial therapy of unresectable metastatic colorectal cancer (mCRC).mp4
FOxTROT neoadjuvant FOLFOX chemotherapy with or without panitumumab (Pan) for patients (pts) with locally advanced.mp4
FRACTION-RCC Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory.mp4
FRACTION-RCC Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory.pdf
Frailty and neurocognitive decline in young adult survivors of childhood cancer A longitudinal analysis from the St. Jude lifetime cohort.mp4
Frequency and prediction of non-medical opioid use behaviors (NMOU) among advanced cancer patients.mp4
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.mp4
GAIN-2 Neo-adjuvant phase III trial to compare intense dose-dense chemotherapy (CT) to tailored dose-dense CT.mp4
Gait speed and recommended treatment intensity among older adults with blood cancers.mp4
Gastrointestinal Cancer-Colorectal and Anal.mp4
Gastrointestinal Cancer-Colorectal and Anal.pdf
Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary.mp4
Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary.pdf
GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against.mp4
Gender differences in faculty rank and subspecialty choice in academic medical oncology.mp4
Genetic profiling and the response to RET inhibitors in RET fusion positive non-small cell lung cancer (NSCLC).mp4
Genitourinary Cancer-Kidney and Bladder.mp4
Genitourinary Cancer-Kidney and Bladder.pdf
Genitourinary Cancer-Prostate, Testicular, and Penile.mp4
Genitourinary Cancer-Prostate, Testicular, and Penile.pdf
Genomic landscape of angiosarcoma A targeted and immunotherapy biomarker analysis of 143 patients.mp4
Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States.mp4
Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of cancer therapy.mp4
Geographic disparity of outcome in patients with cancer over decades The surveillance, epidemiology, and end results.mp4
Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer.mp4
Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer.pdf
Get Up and Go Impact of Geriatric Assessment-Driven Interventions.mp4
Get Up and Go Impact of Geriatric Assessment-Driven Interventions.pdf
Getting in Early New Frontiers in Palliative Care Interventions.mp4
Getting in Early New Frontiers in Palliative Care Interventions.pdf
Getting to the Heart of Late Effects.mp4
Getting to the Heart of Late Effects.pdf
Glasdegib (GLAS) plus low-dose cytarabine (LDAC) in AML or MDS BRIGHT AML 1003 final report and four-year overall survival (OS) follow-up.mp4
Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS).mp4
Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer.mp4
Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma.mp4
GO39775 A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A.mp4
Going Virtual Bringing Genetic Medicine Close to Home.mp4
Going Virtual Bringing Genetic Medicine Close to Home.pdf
Guest Speaker’s Address.mp4
Guns N’ Roses CAR T in Multiple Myeloma.mp4
Guns N’ Roses CAR T in Multiple Myeloma.pdf
Gynecologic Cancer.mp4
Gynecologic Cancer.pdf
HANNA Real-world outcomes from an observational study with nivolumab in patients with recurrent.mp4
Harness the Immune System for Pediatric Solid Tumors.mp4
Harness the Immune System for Pediatric Solid Tumors.pdf
Has Cancer MET Its Match.mp4
Has Cancer MET Its Match.pdf
Head and Neck Cancer Immunity Cycle Challenges and Opportunities.mp4
Head and Neck Cancer.mp4
Head and Neck Cancer.pdf
Health and cancer concerns among siblings of childhood cancer survivors.mp4
Health Services Research and Quality Improvement Highlights.mp4
Health Services Research and Quality Improvement Highlights.pdf
Health-related quality of life (HRQL) in patients with advanced cutaneous squamous cell carcinoma (CSCC) treated with cemiplimab.mp4
Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant.mp4
Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS).mp4
Hematologic Malignancies – Leukemia, MDS, and Allotransplant.mp4
Hematologic Malignancies – Leukemia, MDS, and Allotransplant.pdf
Hematologic Malignancies – Lymphoma and CLL.mp4
Hematologic Malignancies – Lymphoma and CLL.pdf
Hematologic Malignancies – Plasma Cell Dyscrasia.mp4
Hematologic Malignancies – Plasma Cell Dyscrasia.pdf
Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with unresectable hepatocellular carcinoma (HAIROX).mp4
HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients.mp4
HERO phase III trial Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.mp4
HERO phase III trial Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.pdf
High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3.mp4
High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC).mp4
High-dose vitamin D supplementation for cancer-treatment-induced bone loss in 164 breast and prostate cancer patient.mp4
High-risk breast cancer genes at 8q22-24 and their role in over 5,000 patients evaluated with the 70-gene risk of recurrence assay.mp4
Histopathologic validation of the sentinel node technique in early-stage cervical cancer patients.mp4
Histopathologic validation of the sentinel node technique in early-stage cervical cancer patients.pdf
Hitting the Bullseye Evolving Role of Targeted and Immune Therapy in Gastroesophageal Cancers.mp4
Hitting the Bullseye Evolving Role of Targeted and Immune Therapy in Gastroesophageal Cancers.pdf
Home ePRO compliance in prostate cancer clinical studies.mp4
Home to Stay!.mp4
Home to Stay!.pdf
Home-based management of cancer patients (CPs) experiencing toxicities while on anticancer treatment.mp4
Home-based management of cancer patients (CPs) experiencing toxicities while on anticancer treatment.pdf
Hospitalizations following cancer diagnosis National values for frequency, duration, and charges.mp4
HSD3B1 (1245A C) polymorphism and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients.mp4
Hyponatremia could be an important prognostic factor for oncology patients Result of a retrospective study.mp4
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed.mp4
Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed.pdf
Identification of FGFR2 3 fusions from clinical cfDNA NGS using a de novo fusion caller.mp4
Identification of pathogenic ROS1 alterations in cell-free DNA (cfDNA) from patients with breast cancer.mp4
Identifying and Validating Novel Biomakers in Glioma.mp4
Identifying and Validating Novel Biomakers in Glioma.pdf
IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients.mp4
IDH-Mutated Low-Grade Glioma An Evolving Landscape.mp4
IDH-Mutated Low-Grade Glioma An Evolving Landscape.pdf
IGM-8444 as a potent agonistic Death Receptor 5 (DR5) IgM antibody Induction of tumor cytotoxicity, combination.mp4
Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.mp4
Immune functional portraits of head and neck cancer using next generation sequencing.mp4
Immune microenvironment profiling of breast cancer brain metastases using multiplex immunofluorescence.mp4
Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.mp4
Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.mp4
Immunohistochemical characterization of anaplastic large cell lymphoma using tissue microarray.mp4
IMMUNOSARC a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I II trial of sunitinib.mp4
Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.mp4
Impact of baseline symptom burden as assessed by patient-reported outcomes (PROs) on overall survival (OS).mp4
Impact of body composition on toxicity and pathological complete response in locally advanced breast cancer (BC).mp4
Impact of body measurements (BM) on overall survival (OS) and quality of life (QoL) in real-world patients (pts).mp4
Impact of chemotherapy alone or in combination with an anti-angiogenic on the immune tumor microenvironment (TME).mp4
Impact of chemotherapy alone or in combination with an anti-angiogenic on the immune tumor microenvironment (TME).pdf
Impact of delays in initiation of adjuvant endocrine therapy and survival among patients with breast cancer.mp4
Impact of empirically eliminating 5-fluorouracil (5-FU) bolus and leucovorin (LV) in patients with metastatic.mp4
Impact of immune checkpoint and BRAF inhibitors on the incidence of second primary malignancies (SPM) in melanoma.mp4
Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant.mp4
Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.mp4
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET CT on clinical management of patients (pts).mp4
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET CT on clinical management of patients (pts).pdf
Impact of radiotherapy on risk of adverse events in patients receiving immunotherapy.mp4
Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.mp4
Impact of renal impairment on clinical outcomes in patients (pts) with locally advanced or metastatic (LA M).mp4
Impact of SWI SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.mp4
Implementation issues in screening Do you see me now.mp4
Implementation of systematic germline genetic testing (GT) for metastatic prostate cancer (mPC) patients.mp4
IMpower150 Exploratory analysis of brain metastases development.mp4
Improved prognostication for lung cancer patients from computed tomography imaging using deep learning.mp4
Improving cancer pain control Potential impact of CYP2D6 pharmacogenomic (PGx) testing in oncology (Onc) patients.mp4
Improving Ewing Sarcoma Therapy Through Front-End and Back-End Chemotherapy Approaches.pdf
Improving Our Aim Targeted Therapy Advances in Breast Cancer.mp4
Improving Outcomes in Neuroblastoma Cooperating Agents and Cooperating Groups.mp4
Improving Outcomes in Neuroblastoma Cooperating Agents and Cooperating Groups.pdf
Improving Pediatric Allogenic Transplantation and Survivorship.mp4
Improving Pediatric Allogenic Transplantation and Survivorship.pdf
IMvigor010 Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs).mp4
IMvigor010 Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs).pdf
In vitro and in vivo characterization of MDNA11 A long-acting ‘beta-only’ IL-2 superkine in syngeneic mice tumor.mp4
Incidence of graft versus host disease in peri transplant hospitalization after clostridium difficile infection.mp4
Incidence of large granular lymphocytosis (LGL) in patients with late cytopenias after allogeneic blood or marrow transplantation (AlloBMT).mp4
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer.mp4
Inclusion of economic outcomes in NCI grants A portfolio analysis.mp4
Increased pathological complete response rate with neoadjuvant denosumab in locally advanced giant cell tumor.mp4
INDIGO A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts).mp4
Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC).mp4
Individulizing the Adjuvant Approach for the Pancreatic Cancer and Expanding Options in Advanced Pancreatic NETs.mp4
INDUCE-1 Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609).mp4
INDUCE-3 A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS).mp4
Infigratinib and treatment response in advanced unresectable or metastatic urothelial carcinoma in first-line and later-line.mp4
Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA).mp4
Inflammatory and clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN).mp4
Influence of antibiotic therapy (ATB) on oncological outcomes of metastatic non-small cell lung cancer (mNSCLC) patients.mp4
Influence of BRCA pathogenic variants in the benefit of secondary cytoreductive surgery.mp4
Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC).mp4
Initial experience of the adjuvant treatments to the local tumor for metastatic prostate cancer.mp4
Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients.mp4
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib.mp4
Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib.pdf
Innovation in Neoadjuvant Therapy.mp4
Innovations in Induction Therapy in Non-Small Cell Lung Cancer.mp4
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810).mp4
Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy.mp4
Integrated geriatric assessment and treatment (INTEGERATE) in older people with cancer planned for systemic anticancer therapy.pdf
Integrative tumor and immune cell multi-omic analyses to predict melanoma response to immune checkpoint blockade.mp4
Interim analysis (IA) of OPTIC A dose-ranging study of three ponatinib (PON) starting doses.mp4
Interim analysis (IA) of OPTIC A dose-ranging study of three ponatinib (PON) starting doses.pdf
Interim analysis of ZUMA-5 A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed.mp4
Interim analysis of ZUMA-5 A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed.pdf
Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients.mp4
Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients.pdf
Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients.mp4
Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy.mp4
Intra-operative radiation therapy as salvage treatment option for recurrent glioblastoma multiforme.mp4
Intratumoral exposure levels of pentaglutamated pemetrexed following treatment with LEAF-1401 and pemetrexed.mp4
Intrathoracic versus cervical anastomosis after minimally invasive esophagectomy for esophageal cancer.mp4
Investigating Appropriate Dose, Schedule, and Setting of PD-1 and CTLA-4 Blockade.mp4
Investigating Appropriate Dose, Schedule, and Setting of PD-1 and CTLA-4 Blockade.pdf
Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients.mp4
IO IO How Far Do We Go.mp4
IPAX-1 Phase I II study of 131I-iodo-phenylalanine combined with external radiation therapy as treatment.mp4
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM).mp4
Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM).pdf
Ipilimumab challenge re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated.mp4
Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving.mp4
Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving.pdf
Is PSMA Right on Target.mp4
Is PSMA Right on Target.pdf
It’s All About Access How Resources Affect Who Lives and Dies.mp4
It’s Not All Drugs Nonpharmacologic Interventions for Cancer Control.mp4
It’s Not All Drugs Nonpharmacologic Interventions for Cancer Control.pdf
It’s Not What You Say, It’s How You Say It New Genetic Testing Delivery Models.mp4
It’s Not What You Say, It’s How You Say It New Genetic Testing Delivery Models.pdf
Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing.mp4
Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed refractory (RR) primary systemic AL amyloidosis (AL) patients (pts).mp4
Just-in-Time Teaching (JiTT) screencasts for the resident inpatient oncology service.mp4
Juvenile granulosa cell tumor An interim report from the international ovarian and testicular stromal tumor (OTST) registry.mp4
KarMMa-RW A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM).mp4
KEAP1 NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.mp4
KEYNOTE-048 Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C).mp4
KEYNOTE-048 Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C).pdf
KEYNOTE-199 cohorts (C) 4 and 5 Phase II study of pembrolizumab (pembro) plus enzalutamide (enza).mp4
KEYNOTE-204 Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV).mp4
KEYNOTE-204 Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV).pdf
KEYNOTE-355 Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo.mp4
KEYNOTE-355 Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo.pdf
KEYNOTE-604 Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy.mp4
KEYNOTE-604 Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy.pdf
KITE-439 A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed refractory.mp4
Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC).mp4
Late toxicities and recurrences in patients with clinical stage I nonseminomatous germ cell tumor after one cycle.mp4
Launch prices and price developments of cancer drugs in the United States and Europe.pdf
Learning to Juggle Targeted and Immune Therapy Options in Advanced Gastroesophageal Cancers.mp4
Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR).mp4
Let’s Get a Move On!.mp4
Let’s Get a Move On!.pdf
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).mp4
Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).pdf
Leveraging Big Data to Inform Cancer Care Delivery and Policy.pdf
Leveraging Biomarkers and Clinical Characteristics to Guide Adjuvant Therapy.mp4
Leveraging Biomarkers and Clinical Characteristics to Guide Adjuvant Therapy.pdf
Limited-Stage Small Cell Lung Cancer Have We Finally Defined Radiation Standards.mp4
Limited-Stage Small Cell Lung Cancer Have We Finally Defined Radiation Standards.pdf
Liquid biopsy of the immune environment Evaluation of peripheral blood mononuclear cells (PBMCs) with CyTOF.mp4
Liquid Profiling to Inform CDK4-6 Therapy.mp4
Liquid Profiling to Inform CDK4-6 Therapy.pdf
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed refractory (R R).mp4
Longitudinal cumulative dose A novel measure to assess multiple dimensions of chemotherapy adherence over time.mp4
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600-mutant melanoma.mp4
Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600-mutant melanoma.pdf
Long-term cancer survival in cohorts of U.S. health professionals.mp4
Long-term financial outcomes and quality of life in partners of colorectal cancer survivors.mp4
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients.mp4
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients.pdf
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies.mp4
Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced.mp4
Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia.mp4
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT).mp4
Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT).pdf
Long-term immune-related adverse events under PD-1 inhibitors a multicenter prospective cohort study (MELBASE).mp4
Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.mp4
Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer.pdf
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).mp4
Long-term survival from pembrolizumab (pembro) completion and pembro retreatment.mp4
Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R R AML ADMIRAL trial follow-up.mp4
Looking Ahead to the Next Generation of Immunotherapy Trials in Sarcoma.mp4
Looking Back on COVID in order to Move Forward.mp4
Looking Back on COVID in order to Move Forward.pdf
Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC).mp4
Lost in the Woods Seeking Novel Therapies from the Patient’s Perspective.mp4
Lost in the Woods Seeking Novel Therapies from the Patient’s Perspective.pdf
Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer.mp4
Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer.pdf
Lower-dosing ponatinib in pre-treated GIST Results of the POETIG phase II trial.mp4
Lung Cancer – Non-small Cell Local-regional Small Cell Other.mp4
Lung Cancer – Non-small Cell Local-regional Small Cell Other.pdf
Lung Cancer – Non-small Cell Metastatic.mp4
Lung Cancer – Non-small Cell Metastatic.pdf
Lung cancer as a subsequent neoplasm A report from the Childhood Cancer Survivor Study (CCSS).mp4
Lung cancer screening knowledge in four internal medicine university programs.mp4
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors – Copy.mp4
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors.pdf
Machine learning guided adjuvant treatment of head and neck cancer – Copy.mp4
Madness in the Method Using Risk Assessment Models Correctly – Copy.mp4
Madness in the Method Using Risk Assessment Models Correctly.pdf
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L).mp4
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L).pdf
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts).mp4
Maintenance oral etoposide (VP-16) after high-dose chemotherapy (HDCT) for patients with relapsed metastatic germ-cell tumors (mGCT).mp4
Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma.mp4
Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma.pdf
Mammography adherence among medically underserved women undergoing cancer genetic risk assessment.mp4
Mammography utilization among women with a negative circulating tumor DNA-based early cancer detection test.mp4
Man Versus Machine Is Artificial Intelligence Ready for Clinical Practice.mp4
Man Versus Machine Is Artificial Intelligence Ready for Clinical Practice.pdf
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib.mp4
Mantle cell lymphoma initial report from the North American Mantle Cell Lymphoma Consortium.mp4
Maximizing Benefit Through Biomarker-Directed Therapy.mp4
Maximizing Benefit Through Biomarker-Directed Therapy.pdf
Maximizing the Benefits of Targeted Therapies.mp4
Maximizing the Benefits of Targeted Therapies.pdf
MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin–4 receptor (IL4R).mp4
Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation.mp4
MEeT the Professor Where Do We Go Now.mp4
MEeT the Professor Where Do We Go Now.pdf
Meeting the Needs of Patients With Advanced Cancer Systems Approaches to Palliative Care Delivery.mp4
Meeting the unMET Need!.mp4
Meeting the unMET Need!.pdf
Melanoma Skin Cancers.mp4
Melanoma Skin Cancers.pdf
Meta-analysis of cyclin-dependent kinase (CDK) 4 6 inhibitors with endocrine therapy versus endocrine.mp4
Metabolic syndrome, metabolic comorbid conditions, and risk of early-onset colorectal cancer.mp4
Methodology, results, and publication of oncology clinical trials Insights from all the world’s randomized.mp4
Mind the Gap Identifying Disparities and Actionable Insights.mp4
Mind the Gap Identifying Disparities and Actionable Insights.pdf
MINDACT Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance.mp4
MINDACT Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance.pdf
Mirvetuximab soravtansine, a folate receptor alpha (FRà)-targeting antibody-drug conjugate (ADC), in combination.mp4
Mirvetuximab soravtansine, a folate receptor alpha (FRà)-targeting antibody-drug conjugate (ADC), in combination.pdf
Mismatch between mortality burden and number of FDA registration trials in highly lethal cancers.mp4
MiST1 A phase IIa trial of rucaparib in patients harbouring BAP1 BRCA1 deficient relapsed malignant mesothelioma.mp4
Mobile apps Breaking barriers to early cancer detection in underserved communities.mp4
Model to predict brain metastasis (BM) in patients with metastatic germ-cell tumors (mGCT).mp4
Modulation of inhibitory signals in CAR T cells leads to improved activity against glioblastoma.mp4
Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA).mp4
Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts).mp4
Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).mp4
MONARCH 2 subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy.mp4
Morbidity Associated With Cancer Screening and Treatment A Radiation Oncologist Perspective.mp4
Morbidity Associated With Cancer Screening and Treatment A Radiation Oncologist Perspective.pdf
Moving Beyond the Standard Treatment for Biliary Tract and Hepatocellular Cancers.mp4
Moving Beyond the Standard Treatment for Biliary Tract and Hepatocellular Cancers.pdf
Moving Closer to Less Progress in De-escalation After Resection.mp4
Moving the Bar Innovative Agents for Advanced Hepatocellular Carcinoma.mp4
Moving the Needle in High-Risk Lymphoma.mp4
Multicentre randomized phase II trial of olaparib as maintenance therapy in platinum-sensitive advanced endometrial carcinoma.mp4
Multi-institutional comparative effectiveness of advanced cancer longitudinal imaging response evaluation methods.mp4
Multinational Collaboration Paves the Way to Randomized Trials in Ewing Sarcoma.mp4
Multinational Collaboration Paves the Way to Randomized Trials in Ewing Sarcoma.pdf
Multi-omics analysis of mantle cell lymphoma reveals an immune-cold tumor microenvironment associated with ibrutinib resistance.mp4
Multiple myeloma (MM) vaccination (influenza, FV and pneumococcal, PV) rates worldwide and impact on infection, hospitalization, and death.mp4
Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).mp4
Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML).pdf
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA.mp4
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central.mp4
Myelodysplastic syndrome survival and secondary AML trends in the United States.mp4
Myeloid Disorders The What and the Why of Treatment.mp4
Myeloid Disorders The What and the Why of Treatment.pdf
Nano-enabled Medicine.mp4
Nano-enabled Medicine.pdf
NAPOLI-3 An open-label, randomized, phase III study of first-line liposomal irinotecan + 5-fluorouracil.mp4
NEJ026 Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.mp4
NEJ026 Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.pdf
Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).mp4
Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC).pdf
Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX).mp4
Neoadjuvant treatment with chemotherapy or chemoradiation in stage III non-small cell lung cancer.mp4
Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit.mp4
Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit.pdf
Neuromuscular dysfunction and associated health socioeconomic outcomes.mp4
New and Updated Pivotal Trials of Single Agent and Combination Immunocheckpoint Blockers in Bladder and Kidney Cancers.mp4
New and Updated Pivotal Trials of Single Agent and Combination Immunocheckpoint Blockers in Bladder and Kidney Cancers.pdf
New Antibodies, New Targets Are We Making Progress.mp4
New Antibodies, New Targets Are We Making Progress.pdf
New Combinations in Endometrial Cancer….Finally!.mp4
New Combinations in Endometrial Cancer….Finally!.pdf
New Kids on the Block (NKOTB) Novel Therapies in Multiple Myeloma.mp4
New Kids on the Block (NKOTB) Novel Therapies in Multiple Myeloma.pdf
New Options for Advanced Sarcomas.mp4
New Options for Advanced Sarcomas.pdf
Nickel and dimed Parking fees at NCI-designated cancer centers.mp4
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs).mp4
Niraparib exposure-response relationship in patients (pts) with newly diagnosed advanced ovarian cancer (AOC).mp4
NIVACOR Phase II study of nivolumab in combination with FOLFOXIRI bevacizumab in first-line chemotherapy.mp4
NivoCUP An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.mp4
NivoCUP An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.pdf
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L).mp4
Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L).pdf
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high.mp4
Nivolumab (NIVO) plus ipilimumab (IPI) with two cycles of chemotherapy (chemo) in first-line metastatic.mp4
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer.mp4
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer.pdf
Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA).mp4
NOMINATOR Feasibility of genomic testing of rare cancers to match cancer to treatment.mp4
NOMINATOR Feasibility of genomic testing of rare cancers to match cancer to treatment.pdf
Non-invasive detection of urothelial carcinoma (UC) by cost-effective low-coverage whole genome sequencing.mp4
Noninvasive identification of lineage-specific circular RNA for ER-positive breast cancer.mp4
Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).mp4
Novel Antimitotic Drug Delivery and Combination Strategies.mp4
Novel Antimitotic Drug Delivery and Combination Strategies.pdf
Novel Approaches to Optimizing Immune Checkpoint Inhibitors.mp4
Novel Approaches to Optimizing Immune Checkpoint Inhibitors.pdf
Novel biomarker panel based on cellular and soluble checkpoint proteins for PD-1 PD-L1 blockade treatment efficacy.mp4
Novel Biomarkers in Prostate Cancer Is the Tissue the Issue.mp4
Novel Biomarkers in Prostate Cancer Is the Tissue the Issue.pdf
Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative.mp4
Novel Immunotherapy Delivery Strategies Sticking It to the Tumor.mp4
Novel Immunotherapy Strategies.mp4
Novel Immunotherapy-Based Therapy in Metastatic Urothelial Cancers.mp4
Novel Inductions in Acute Myeloid Leukemia in Older Patients Did Longer Follow-up Provide Us Unique Insights.mp4
Novel Inductions in Acute Myeloid Leukemia in Older Patients Did Longer Follow-up Provide Us Unique Insights.pdf
Novel methylated DNA markers in plasma detect distant recurrence of colorectal cancer.mp4
Novel Targeted Therapy Approaches.mp4
Novel Targeted Therapy Approaches.pdf
Novel Targets and Combinations for Refractory Solid Tumors.mp4
Novel Targets and Combinations for Refractory Solid Tumors.pdf
NSCLC Integrating the ‘Yale model shared decision-making solution’ into the practice setting.mp4
Nurturing an Orphan Drug.mp4
Nurturing an Orphan Drug.pdf
Obstetrical and perinatal complications in survivors of childhood, adolescent, and young adult cancer.mp4
Of Bugs and Drugs How Our Microbiome Saves Us.mp4
Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1 2 inactivating mutations.mp4
Olaparib (O) in patients (pts) with prostate cancer with BRCA1 2 inactivating mutations.mp4
Olaparib maintenance monotherapy for non-germline BRCA1 2-mutated (non-gBRCAm) platinum-sensitive relapsed.mp4
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2.mp4
Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm).mp4
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG.mp4
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed refractory multiple myeloma (MM).mp4
Oncogeriatric Prehab Optimizing Older Adults for Cancer Treatment.mp4
Oncogeriatric Prehab Optimizing Older Adults for Cancer Treatment.pdf
Oncological outcomes of 356 patients undergoing salvage focal ablative HIFU or cryotherapy following radiation failure.mp4
One Size Does Not Fit ALL Modifiers of Response and Toxicity.mp4
Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients.mp4
Opening Remarks.mp4
Opening Remarks.pdf
Open-label pilot study of genetically engineered NY-ESO-1-specific t cells (GSK3377794) alone or in combination.mp4
Optimal Management and Monitoring of Primary Germ Cell Tumors of the Central Nervous System.mp4
Optimal Management and Monitoring of Primary Germ Cell Tumors of the Central Nervous System.pdf
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC).mp4
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC).pdf
Optimizing Imaging to Predict Glioblastoma Outcomes.mp4
Optimizing Imaging to Predict Glioblastoma Outcomes.pdf
Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma.pdf
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts).mp4
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts).pdf
Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC.mp4
Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC.pdf
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations.mp4
Outcome in patients with refractory high-risk neuroblastoma.mp4
Outcomes and prognostic factors of patients (pts) with metastatic colorectal cancer (mCRC) who underwent.mp4
Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials.mp4
Outcomes for black versus white women with stage IV breast cancer enrolled on investigator-initiated clinical trials at Emory.mp4
Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL).mp4
Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL).pdf
Outcomes in older patients with high-risk secondary AML who achieved remission with CPX-351 versus 7+3 but.mp4
Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV).mp4
Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI).mp4
Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI).pdf
Out-of-pocket cost of screening with breast MRI for women at high risk for breast cancer.mp4
Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing.mp4
Ovarian Cancer Hot, Timely, and Painless.mp4
Ovarian Cancer Hot, Timely, and Painless.pdf
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin.mp4
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin.pdf
Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets).mp4
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT).mp4
Overall survival (OS) with docetaxel (D) vs novel hormonal therapy (NHT) with abiraterone (A) or enzalutamide (E).mp4
Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer.mp4
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb.mp4
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb.pdf
Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis.mp4
PANasta Trial Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy.mp4
Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape.mp4
Panel-based methodology for assessing the impact of public policies on cancer patients and survivors.mp4
PARSIFAL A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant.mp4
PARSIFAL A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant.pdf
Patient-reported care satisfaction and symptom burden in hospitalized patients with cancer.mp4
Patient-reported distress and healthcare utilization in patients with advanced cancer.mp4
Patient-reported health literacy and numeracy among new patients seeking consultation at a comprehensive cancer center.mp4
Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo).mp4
Patient-reported out-of-pocket costs and financial toxicity during early-phase oncology clinical trials.mp4
Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).mp4
PCR-based comprehensive genomic profiling (PCR-CGP) Feasibility from 20,000 tumor tissue specimens (TTS).mp4
PD-1 protein and gene expression in early breast cancer Prognostic implications.mp4
PD-1 Treatment Outcomes Informed by Gene Expression Profiles.mp4
PD-1 Treatment Outcomes Informed by Gene Expression Profiles.pdf
PDIGREE An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO).mp4
PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria.mp4
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous.mp4
‘Pearls’ for Newly Diagnosed High-Risk Multiple Myeloma Finding the Right ‘Jam’.mp4
‘Pearls’ for Newly Diagnosed High-Risk Multiple Myeloma Finding the Right ‘Jam’.pdf
Pediatric Oncology.mp4
Pediatric Oncology.pdf
Pediatric Precision Oncology 2020.mp4
Pediatric Precision Oncology 2020.pdf
Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS.mp4
Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi).mp4
Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic.mp4
Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric.mp4
Pembrolizumab for previously treated advanced anal squamous cell carcinoma Pooled results from the KEYNOTE-028.mp4
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC).mp4
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC).pdf
Pembrolizumab versus chemotherapy for microsatellite instability-high mismatch repair deficient metastatic.mp4
Pembrolizumab versus chemotherapy for microsatellite instability-high mismatch repair deficient metastatic.pdf
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal.mp4
Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal.pdf
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.mp4
Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.pdf
Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG).mp4
Pen-866, a miniature drug conjugate of a heat shock protein 90 (HSP90) ligand linked to SN38 for patients.mp4
Performance of the IBIS Tyrer-Cuzick (TC) Model by race ethnicity in the Women’s Health Initiative.mp4
Performance of the IBIS Tyrer-Cuzick (TC) Model by race ethnicity in the Women’s Health Initiative.pdf
Perioperative circulating tumor DNA analysis to predict patient prognosis in liver cancer.mp4
Perioperative chemotherapy versus adjuvant chemoradiation in resectable gastric cancer A national cancer database analysis.mp4
Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers.mp4
Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers.pdf
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma.pdf
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric.mp4
Perioperative Therapy in Soft Tissue Sarcomas The Debate Continues.mp4
Perioperative Therapy in Soft Tissue Sarcomas The Debate Continues.pdf
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable.mp4
Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable.pdf
Peripheral blood immune correlates associated with TGF-á inhibition (galunisertib) and stereotactic body radiotherapy (SBRT).mp4
Peripheral motor and sensory neuropathy in survivors of childhood central nervous system (CNS) tumors.mp4
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA) Secondary and final primary efficacy analyses.mp4
PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+).mp4
Pilot study on outcome and antitumor efficacy of an autologous cancer cell vaccine applied in patients with advanced solid tumors.mp4
Pilot study on outcome and antitumor efficacy of an autologous cancer cell vaccine applied in patients with advanced solid tumors.pdf
Pivotal DREAMM-2 study Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed.mp4
Pivotal trial endpoints and prices of cancer drugs in the US and Europe.mp4
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated.mp4
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study.mp4
Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study.pdf
Plasma-derived cfDNA to reveal potential biomarkers of response prediction and monitoring in non-small cell lung cancer.mp4
Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens.mp4
POLARGO Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx).mp4
POLO Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib.mp4
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.mp4
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.pdf
Population genetic screening for hereditary breast and ovarian cancer in at-risk patients.mp4
Population-adjusted indirect treatment comparison (PAITC) of maintenance PARP inhibitor (PARPi) with or without.mp4
Population-based prostate cancer screening using a prospective, blinded, paired screen-positive comparison of PSA and fast MRI.mp4
Post-hoc power of clinical trials supporting anticancer drug approval by FDA.mp4
Post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice.mp4
Post-traumatic stress symptoms in hematopoietic stem cell transplant (HCT) recipients.mp4
Post-traumatic stress symptoms in hematopoietic stem cell transplant (HCT) recipients.pdf
Potential germline findings identified during somatic tumor testing Room for improvement.mp4
Practice gaps and challenges integrating new immuno-oncology agents in the treatment of cancer patients in the United States.mp4
PrE0505 Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed.mp4
PrE0505 Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed.pdf
Precision Pounds Poison Promise and Progress.mp4
Preclinical evaluation of KZR-261, a novel small molecule inhibitor of Sec61.mp4
Prediabetes and progression to diabetes among adult survivors of childhood cancer in the St. Jude Lifetime Cohort.mp4
Predicting nodal positivity in women with hormone receptor-positive (HR+), early stage breast cancer (ESBC).mp4
Prediction of the molecular status in non-small cell lung cancer based on metastatic pattern.mp4
Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.mp4
Predictive survival ability of patient-reported in comparison to physician-reported performance status in solid malignancies.mp4
Predictive value of a CLIA-approved organoid based drug sensitivity test.mp4
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients.mp4
Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.mp4
Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.pdf
Preliminary clinical pharmacokinetics and dose-response to support a phase II dose selection for CX-2009.mp4
Preliminary dose escalation results from a phase I II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate).mp4
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study.mp4
Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study.mp4
Preliminary population pharmacokinetics supports phase II dose selection for masked anti-PD-L1 antibody CX-072.mp4
Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated.mp4
Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated.pdf
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.mp4
Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.pdf
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts).mp4
President’s Address.mp4
Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome.mp4
Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC.mp4
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus.mp4
Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus.pdf
Primary analysis of KAITLIN A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab.mp4
Primary analysis of KAITLIN A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab.pdf
Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone.mp4
Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone.pdf
Primary Central Nervous System Lymphoma Is There an Optimal First-Line Treatment.mp4
Primary cytoreductive surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for FIGO stage III.mp4
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer.mp4
Primary results of NRG Oncology NSABP B-43 Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT).mp4
Primary results of NRG Oncology NSABP B-43 Phase III trial comparing concurrent trastuzumab (T) and radiation therapy (RT).pdf
Prior authorization process improvement for pain medications in an oncology unit Timely initiation of test claim request form.mp4
ProCAID A randomized double-blind phase II clinical trial of capivasertib (C) in combination with docetaxel.mp4
PROCLAIM-CX-072 Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072.mp4
PROCLAIM-CX-072 Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072.pdf
Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed refractory (R R).mp4
Prognostic and predictive effects of circulating and disseminated tumor cells in breast cancer.mp4
Prognostic differences of RAS mutations Results from South Australian (SA) metastatic colorectal (mCRC) registry.mp4
Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib.mp4
Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib.pdf
Prognostic role of pre-treatment magnetic resonance imaging (MRI) radiomic analysis in patients with squamous cell.mp4
Project facilitate A review of the FDA oncology center of excellence expanded access pilot program.mp4
Projection of cancer incidence and death to 2040 in the US Impact of cancer screening and a changing demographic.mp4
Promising Therapeutic Targets in Prostate Cancer.mp4
PROREPAIR-A Clinical and molecular characterization study of prostate cancer (PC) patients.mp4
Prospective study comparing self-administered geriatric assessment to provider’s routine clinical assessment of older patients.mp4
Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care.mp4
Prostate cancer relative survival by stage and race ethnicity, United States, 2001 to 2015.mp4
Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide.mp4
Proteomic profiling to identify therapeutics targets in glioblastoma (GBM).mp4
Psychosocial outcomes following surgery in women with unilateral, nonhereditary breast cancer.mp4
Putting Circulating Tumor DNA to Work Patient Selection for Targeted Therapies and Monitoring of Response and Resistance.mp4
Putting Circulating Tumor DNA to Work Patient Selection for Targeted Therapies and Monitoring of Response and Resistance.pdf
Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE) A randomized phase III trial.mp4
Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE) A randomized phase III trial.pdf
Pharmacodynamic (PD) responses drive dose schedule selection of CC-92480, a novel CELMoD agent.mp4
Pharmacodynamic, safety, and efficacy results of a phase I II trial of intratumoral INT230-6 alone (IT-01) or in.mp4
Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.mp4
Phase I Alexander study of AUTO3, the first CD19 22 dual targeting CAR T cell therapy, with pembrolizumab.mp4
Phase I Alexander study of AUTO3, the first CD19 22 dual targeting CAR T cell therapy, with pembrolizumab.pdf
Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC).mp4
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.mp4
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.pdf
Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration.mp4
Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts).mp4
Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC).mp4
Phase I II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy.mp4
Phase I II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.mp4
Phase I II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.pdf
Phase I II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse.mp4
Phase I II study of SAR439859, an oral selective estrogen receptor degrader (SERD).mp4
Phase I II study of T-DM1 alone versus T-DM1 and metronomic temozolomide in secondary prevention of.mp4
Phase I II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination.mp4
Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8 CKB pathway.mp4
Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8 CKB pathway.pdf
Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3á) inhibitor.mp4
Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3á) inhibitor.pdf
Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration.mp4
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting.mp4
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic.mp4
Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3.mp4
Phase I study of BPM31510 and vitamin K in patients with high grade glioma recurrent after a bevacizumab-containing.mp4
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients.mp4
Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.mp4
Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.mp4
Phase I study of proton therapy in adjuvant pancreatic cancer (PROTON-PANC).mp4
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.mp4
Phase I study of regorafenib in combination with vincristine and irinotecan in pediatric patients with recurrent or refractory solid tumors.pdf
Phase I study of rucaparib and irinotecan in advanced solid tumors with homologous recombination deficiency (HRD) mutations.pdf
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic.mp4
Phase I study of tazemetostat, an enhancer of zeste homolog-2 inhibitor, in pediatric pts with relapsed.mp4
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody.mp4
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody.pdf
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.mp4
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.pdf
Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.mp4
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma.mp4
Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma.pdf
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors.mp4
Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA.mp4
Phase Ib II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC).mp4
Phase Ib II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax + – azacitidine.mp4
Phase Ib II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax + – azacitidine.pdf
Phase Ib II trial of tisotumab vedotin (TV) ñ bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent.mp4
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients.mp4
Phase Ib study of BI 836880, a VEGF Ang2-blocking nanobody, in combination with BI 754091, an anti-PD-1 antibody.mp4
Phase Ib study of CPX-351 lower-intensity therapy (LIT) plus venetoclax as first-line treatment for patients.mp4
Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety.mp4
Phase II III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients.mp4
Phase II III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin.mp4
Phase II III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin.pdf
Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC).mp4
Phase II preoperative window study of SAR439859 versus letrozole in post-menopausal women with newly diagnosed.mp4
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA).mp4
Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA).pdf
Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, + – atezolizumab in stage IV non-squamous.mp4
Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ñ tremelimumab (T) and gemcitabine.mp4
Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.mp4
Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421).mp4
Phase II study of antidisialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma (AOST1421).pdf
Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC).mp4
Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed) NCI MATCH EAY131-Z1F.pdf
Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K AKT mTOR pathway.mp4
Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.mp4
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-na‹ve patients (pts) with advanced renal.mp4
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-na‹ve patients (pts) with advanced renal.pdf
Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy.mp4
Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy.pdf
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.mp4
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS).mp4
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS).pdf
Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell.mp4
Phase II study of the oral HIF-2à inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.mp4
Phase II study of the oral HIF-2à inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.pdf
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients.mp4
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1 PD-L1 immune.mp4
Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1 PD-L1 immune.pdf
Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+).mp4
Phase II, multicenter trial of nivolumab (Nivo) and brentuximab vedotin (BV) in patients (Pts) with untreated Hodgkin lymphoma (HL).mp4
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN).mp4
Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events Patient Information and advice).mp4
Phase III randomized controlled trial of eRAPID (electronic patient self-Reporting of Adverse-events Patient Information and advice).pdf
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+ HER2-advanced.mp4
Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous.mp4
Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous.mp4
Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative.mp4
Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative.pdf
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin.mp4
Quality and reliability of online video information of breast cancer in Spanish.mp4
Quality of life (QOL) for the treatment sequence of abiraterone acetate plus prednisone (AAP) followed by enzalutamide (ENZ).mp4
Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week.mp4
Quality of life of adults and children with TRK fusion cancer treated with larotrectinib compared to the general population.mp4
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of lenvatinib plus everolimus versus everolimus.mp4
Radiation-induced changes in the inflammatory microenvironment composition of lung cancer brain metastases.mp4
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC).mp4
Radiotherapy after esophageal cancer stenting (ROCS) A pragmatic randomized controlled trial evaluating.mp4
Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts).mp4
Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP) Outcomes by treatment-emergent ascites.mp4
Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed.mp4
Randomized comparisons of bevacizumab (B) and irinotecan (I), added to temozolomide (T), in children with relapsed.pdf
Randomized phase II clinical trial of cisplatin carboplatin and etoposide (CE) alone or in combination with nivolumab.mp4
Randomized phase II clinical trial of cisplatin carboplatin and etoposide (CE) alone or in combination with nivolumab.pdf
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.mp4
Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma.pdf
Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination.mp4
Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L).mp4
Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with.mp4
Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced.mp4
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced.mp4
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced.pdf
Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT.mp4
Randomized phase II trial comparing the efficacy of standard-dose with high-dose twice-daily thoracic radiotherapy (TRT.pdf
Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic.mp4
Randomized phase II trial of MIBG versus MIBG vincristine irinotecan versus MIBG vorinostat for relapsed refractory neuroblastoma.mp4
Randomized phase II trial of MIBG versus MIBG vincristine irinotecan versus MIBG vorinostat for relapsed refractory neuroblastoma.pdf
Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant.mp4
Randomized phase III study of high-dose methotrexate and whole brain radiotherapy with or without concomitant.pdf
Randomized phase III study of irinotecan cisplatin (IP) versus etoposide cisplatin (EP) for completely resected high-grade.mp4
Randomized phase III study of irinotecan cisplatin (IP) versus etoposide cisplatin (EP) for completely resected high-grade.pdf
Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer.mp4
Randomized trial of a collaborative palliative and oncology care intervention to improve communication.mp4
Randomized trial of a perioperative geriatric intervention for older adults with cancer.mp4
Randomized trial of a perioperative geriatric intervention for older adults with cancer.pdf
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer (NCT03396510).mp4
Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing.mp4
Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing.pdf
Ranking of therapeutic regimens for hormone receptor-positive, HER2-negative, metastatic breast cancer (MBC).mp4
Rapid expansion of M-MDSCs and association with high levels of plasma TSLP and primary resistance to PD-1.mp4
Rare Variant Histologies in Renal Cell Carcinoma Making the Unclear Be More Clear.mp4
Rare Variant Histologies in Renal Cell Carcinoma Making the Unclear Be More Clear.pdf
Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic.mp4
Real-world outcomes of advanced melanoma patients not represented in phase III trials.mp4
Real-world patterns of treatment and recurrence by frailty status among older women with HR-positive.mp4
Real-world performance of blood-based host immune profiling in first-line immunotherapy treatment in advanced-stage.mp4
Real-world survey of pneumonitis radiation pneumonitis among patients with locally advanced non-small cell lung cancer.mp4
Reassessing PI3K Inhibitors in Indolent Lymphomas.mp4
Recurrent Meningioma Are We Ready for Precision Medicine.pdf
Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.mp4
Redefining Cervical Cancer Treatment.mp4
Refining the Understanding of Immune Checkpoint Blockade in Soft Tissue Sarcoma.mp4
Refining the Use of Immunotherapy in Advanced Triple-Negative Breast Cancer.mp4
Refining the Use of Immunotherapy in Advanced Triple-Negative Breast Cancer.pdf
Reflection rounds to facilitate resilience in hematology medical oncology fellows.mp4
Registrational dataset from the phase I II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced.mp4
Relapsed Aggressive B-cell Lymphoma Be Careful Changing Lanes.mp4
Relapsed Aggressive B-cell Lymphoma Be Careful Changing Lanes.pdf
Relationship between caregiver burden and psychological distress among stem cell transplant (SCT) recipients prior to transplant.mp4
Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD) Second part of a phase I-II study.mp4
Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.mp4
Relationships among skeletal muscle, symptom burden, health care use, and survival in hospitalized patients with advanced cancer.pdf
RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell.mp4
RELAY+ Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR).mp4
Reliability and correlations among quality measures for lung, breast, and colorectal cancer.mp4
RE-MIND study A propensity score-based 1 1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus.mp4
Repurposing Novel Agents for Sarcoma Therapy.mp4
Repurposing Novel Agents for Sarcoma Therapy.pdf
RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC).mp4
RESILIENT part II an open-label, randomized, phase III study of liposomal irinotecan injection in patients.mp4
Resource and reimbursement barriers to comprehensive cancer care (CCC) delivery An Association of Community.mp4
Response criteria for intratumoral immunotherapy in solid tumors ItRECIST.mp4
Response to immune checkpoint inhibitor (ICI) rechallenge after high-grade immune related adverse events (irAE) in patients (pts).mp4
Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen.mp4
Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination.mp4
Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination.pdf
Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis.mp4
Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis.pdf
Results from MAGENTA A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic.mp4
Results from MAGENTA A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic.pdf
Results of a prospective phase II national study Prophylactic radical fimbriectomy (NCT01608074).mp4
Results of a phase II randomized trial of cisplatin + – veliparib in metastatic triple-negative breast cancer (TNBC).mp4
Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men.mp4
Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men.pdf
Results of a randomized phase II III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus.mp4
Results of a randomized phase II III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus.pdf
Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT).mp4
Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT).pdf
Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001).mp4
Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC.mp4
Results of crossover phase II component of randomized placebo-controlled trial evaluating oral THC.pdf
Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy.mp4
Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy.pdf
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.mp4
Rhabdomyosarcoma of the female genital tract Long-term outcome and association with DICER1 variation.mp4
Rise of the Machines AI in Predicting Immunotherapy Outcomes.mp4
Rise of the Machines AI in Predicting Immunotherapy Outcomes.pdf
Risk of chronic opioid use after radiation for head and neck cancer A systematic review and meta-analysis.mp4
Risk of secondary hematologic malignancies in patients with ovarian cancer treated with PARP inhibitors.mp4
Role of adjuvant imatinib dose in radically resected GIST harboring KIT exon 9 mutations.mp4
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma.mp4
ROMAN Reduction in oral mucositis with avasopasem manganese (GC4419)-phase III trial in patients.mp4
RTOG 3506 (STEEL) A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.mp4
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC).mp4
Safety and activity of autologous T cells with enhanced NY-ESO-1-specific T-cell receptor (GSK3377794).mp4
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant.mp4
Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.mp4
Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.pdf
Safety and efficacy of biweekly gemcitabine in combination with capecitabine (GemCap) in elderly and frail patients (pts).mp4
Safety and efficacy of gemtuzumab ozogamicin and venetoclax in patients with relapsed or refractory CD33+.mp4
Safety and efficacy of neoadjuvant intravesical oncolytic MV-NIS in patients undergoing radical cystectomy (RC).mp4
Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies.mp4
Safety and efficacy of tazemetostat, an enhancer of zeste-homolog 2 inhibitor, in patients with relapsed.mp4
Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).mp4
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC).mp4
Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC).pdf
Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib II study (FORT-2) of first-line.mp4
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.pdf
Safety of acalabrutinib (Acala) monotherapy in hematologic malignancies Pooled analysis from clinical trials.mp4
Safety outcomes of darolutamide versus apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).mp4
Sarcoma – Sarcoma Highlights.mp4
Sarcoma – Sarcoma Highlights.pdf
Saving the best to the last Can we wait for second-line.mp4
SAVOIR A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).mp4
SAVOIR A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).pdf
SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist.mp4
Scalp cooling to prevent chemotherapy induced alopecia (CIA) in black patients Differences in efficacy.mp4
Seek and Ye Shall Find Germline Mutations in Somatic Profiling.mp4
Seek and Ye Shall Find Germline Mutations in Somatic Profiling.pdf
Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients.mp4
Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients.pdf
Selinexor, daratumumab, and dexamethasone in patients with relapsed refractory multiple myeloma (MM).mp4
Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer.mp4
Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.mp4
Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical.mp4
Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical.pdf
Sharpening the Approach on RET and ALK.mp4
Sharpening the Approach on RET and ALK.pdf
Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer.mp4
Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer.pdf
SIENDO ENGOT-EN5 A randomized phase III trial of maintenance with selinexor placebo after combination.mp4
Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors.mp4
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression.mp4
Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression.pdf
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy.mp4
Single agent PD-1 inhibitor biomarkers in untreated and previously treated advanced RCC.mp4
Single agent targeted agents vs combinations with IO what is the optimal future therapy in advanced Urothelial Cancer.mp4
Single agent targeted agents vs combinations with IO what is the optimal future therapy in advanced Urothelial Cancer.pdf
Single cell mapping of human brain tumors reveals tumor-specific education of tissue-invading leukocytes.mp4
Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression.mp4
Single-center phase I Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM).mp4
Single-center phase I Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM).pdf
Small Cell Lung Cancer Moving Toward Precision Oncology.mp4
Small Cell Lung Cancer Moving Toward Precision Oncology.pdf
Small Molecule Monotherapy and Immuno-Oncology Combinatorial Targeting of Oncogenes and Oncogene.mp4
Small Molecule Monotherapy and Immuno-Oncology Combinatorial Targeting of Oncogenes and Oncogene.pdf
Social media use among NCI designated cancer centers Where is the diversity.mp4
Spatial analysis of tumor immune microenvironment (TIME) in patients treated with Bintrafusp alfa.mp4
SPEARHEAD-1 A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid round cell liposarcoma.mp4
Spice Girls Spicing Up Novel Combination in Multiple Myeloma.mp4
Spice It Up Immunotherapy for RAIR Thyroid Cancers.mp4
Spice It Up Immunotherapy for RAIR Thyroid Cancers.pdf
Sporadic late-onset nemaline myopathy with monoclonal paraprotein as a malignancy rather than disimmunity.mp4
Stability of rare TP53 co-mutations in AML patients.mp4
STAG2-mutated AML patients ASXL1 cohesin binding motif status and mutation landscape.mp4
Stamping Out Treatment Toxicities With Technology.mp4
Stamping Out Treatment Toxicities With Technology.pdf
Statin treatment improves response to anti-PD1 agents in patients with malignant pleural mesothelioma.mp4
Stay Sharp on PARP and More.mp4
Stay Sharp on PARP and More.pdf
Student loan debt and visa status influence on career choices for hematology and medical oncology fellows in the United States.mp4
Study EV-103 Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.mp4
Study EV-103 New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab.mp4
Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients.mp4
Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.mp4
Subcellular partitioning of Kaiso (ZBTB33) as a biomarker to predict overall breast cancer survival.mp4
Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method.mp4
Superior therapy response predictions for patients with glioblastoma (GBM) using Cellworks Singula MyCare-009-03.mp4
Superior therapy response predictions for patients with low-grade glioma (LGG) using Cellworks Singula MyCare-009-04.mp4
Surgery at primary and metastatic sites for stage IV breast cancer (BC) A National Cancer Database (NCDB) analysis.mp4
Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.mp4
Surgical Options and Optional Surgery in Breast Cancer.mp4
Surgical Options and Optional Surgery in Breast Cancer.pdf
Survival differences by race after minimally invasive versus open radical hysterectomy.mp4
Survival impact of multidisciplinary thoracic oncology care in a regional healthcare system.mp4
Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.mp4
Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC).mp4
SWOG S1505 Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine nab-paclitaxel.mp4
SWOG S1505 Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine nab-paclitaxel.pdf
Symptoms and Survivorship.mp4
Symptoms and Survivorship.pdf
Systemic therapy for patients with breast cancer and one to three brain metastases (BM).mp4
Tackling the Unknown, Molecularly.mp4
Tackling the Unknown, Molecularly.pdf
Tackling Treatment Resistance in ER+ Metastatic Breast Cancer.mp4
Tackling Treatment Resistance in ER+ Metastatic Breast Cancer.pdf
Tailoring Neoadjuvant Treatment for Colon and Rectal Cancer.mp4
Tailoring Neoadjuvant Treatment for Colon and Rectal Cancer.pdf
Tailoring Therapy for HER.mp4
TALAPRO-2 a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients.mp4
Talk to Me Advancing Patient Care Through PROs.mp4
Talk to Me Advancing Patient Care Through PROs.pdf
Targeted Interventions in Relapse Refractory Leukemias.mp4
Targeted Oral Agents in Leukemia Testing Combinations and Modulating Dose Intensity.mp4
Targeted Oral Agents in Leukemia Testing Combinations and Modulating Dose Intensity.pdf
Targeted therapy based on germline analysis of tumor-normal sequencing (MSK-IMPACT) in a pan-cancer population.mp4
Targeting Anti-Apoptotic Proteins Combinations With Immuno-Oncology Agents and Mitigating Toxicities.mp4
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer.mp4
Targeting the Immune Microenvironment.mp4
Targeting the Immune Microenvironment.pdf
Targeting Upstream and Downstream Effectors in the PI3K Signaling Cascade.mp4
Targeting Upstream and Downstream Effectors in the PI3K Signaling Cascade.pdf
TBCRC 048 A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic.mp4
TBCRC 048 A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic.pdf
TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.mp4
Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related.mp4
Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence.mp4
Temozolomide-induced hypermutation is associated with high-grade transformation, distant recurrence.pdf
Temsirolimus combined with etoposide and cyclophosphamide for relapsed refractory acute lymphoblastic leukemia.pdf
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined.mp4
Time to Reflect on What We Do Below the Peritoneal Reflection.mp4
Time to Reflect on What We Do Below the Peritoneal Reflection.pdf
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukemia.mp4
Timing of US Food and Drug Administration (FDA) cancer drug approvals relative to publication of clinical trial results.mp4
Tisagenlecleucel (Tisa) for relapsed refractory (r r) acute lymphoblastic leukemia (ALL).mp4
TIVO-3 Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare.mp4
TLC Renal Insufficiency in Multiple Myeloma-Don’t Go Chasing Waterfalls.mp4
TLC Renal Insufficiency in Multiple Myeloma-Don’t Go Chasing Waterfalls.pdf
To ERr Is Human; to Predict, Divine.mp4
To Everything There Is a Season A Time to De-Escalate.mp4
To Everything There Is a Season A Time to De-Escalate.pdf
To Everything There Is a Season A Time to Escalate.mp4
To Everything There Is a Season A Time to Escalate.pdf
To Guide or Not to Guide.mp4
To Guide or Not to Guide.pdf
To the Heart of the Matter Understanding and Improving Cardiovascular Health in Cancer.mp4
To the Heart of the Matter Understanding and Improving Cardiovascular Health in Cancer.pdf
Tolerability and durable respones of the PI3Kë inhibitor ME-401 administered on an intermittent schedule in relapsed.mp4
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients.mp4
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients.pdf
Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas.mp4
Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas.pdf
TOOme A novel computational framework to infer cancer tissue-of-origin by integrating both gene mutation and expression.mp4
Total mesorectal excision compared to local excision in locally advanced rectal cancer achieving complete pathological.mp4
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer.mp4
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer.pdf
TPExtreme randomized trial Quality of Life (QoL) and survival according to second-line treatments in patients.mp4
TPExtreme randomized trial Quality of Life (QoL) and survival according to second-line treatments in patients.pdf
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic.mp4
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic.pdf
Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC).mp4
Tumor detection rates in screening carriers with SDHx-related hereditary paraganglioma-pheochromocytoma.mp4
Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+ – TIM-3- CD8+ T cells.mp4
Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer.mp4
Tumor normal genomic profiling in patients with metastatic solid tumors identifies pathogenic germline variants.mp4
Tumor normal genomic profiling in patients with metastatic solid tumors identifies pathogenic germline variants.pdf
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo).mp4
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo).pdf
Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients.mp4
Tumor-Intrinsic Factors and Immunotherapy Response The Known and Unknown.mp4
Tumor-Intrinsic Factors and Immunotherapy Response The Known and Unknown.pdf
Tumor-Specific Vaccines Lessons Learned from HPV.mp4
Tumor-Specific Vaccines Lessons Learned from HPV.pdf
Tweets, Likes, and Posts Harnessing the Power of Social Media.mp4
Tweets, Likes, and Posts Harnessing the Power of Social Media.pdf
Twenty-four months RFS and updated toxicity data from OpACIN-neo A study to identify the optimal dosing.mp4
Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia.mp4
The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma.mp4
The association between drug industry payments and NCCN guideline panel membership.mp4
The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab.mp4
The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer.mp4
The BRCA founder outreach study Initial results of a digital health model.mp4
The BRCA founder outreach study Initial results of a digital health model.pdf
The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes.mp4
The contribution of clinical subtype to survival differences among patients with de novo and recurrent metastatic.mp4
The correlation between clinical benefit and financial cost of cancer drugs.mp4
The Challenge of Defining a Benchmark for Single-Arm Trials of Combination Therapy in Advanced Sarcoma.mp4
The Challenge of Defining a Benchmark for Single-Arm Trials of Combination Therapy in Advanced Sarcoma.pdf
The development and validation of a novel targeted methylation sequencing technology detecting 0.003 percent.mp4
The economic impact of cancer-related premature mortality in Brazil A human capital approach analysis.mp4
The effect of longitudinal exercise programming in breast cancer patients.mp4
The effect of neutropenia on patient-reported functioning and quality of life (QOL) among palbociclib participants.mp4
The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer.mp4
The impact of adjuvant therapy for non-metastatic thymic carcinoma An analysis of the surveillance, epidemiology.mp4
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab nivolumab.mp4
The impact of pattern of tumor response and other post-treatment histologic features on local recurrence.mp4
The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis.mp4
The impact of residual metabolic primary tumor volume after completion of thoracic irradiation in patients.mp4
The impact of tobacco retail density on overall survival (OS) in lung cancer survivors.mp4
The impact of tumor NGS testing on hereditary cancer risk assessment and population management.mp4
The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent short-term dual MAPK pathway.mp4
The landscape of genomic alterations detected in serial circulating tumor DNA (ctDNA) in clinical progressive.mp4
The Mixed Bag Biomarkers and Therapeutics to Advance the Treatment of ER+ Advanced Disease.mp4
The nature and management of acquired resistance to PD1-based therapy in melanoma.mp4
The next frontier IO combos for recurrent metastatic head and neck cancer.mp4
The oncology hospital at home Health care utilization outcomes from the huntsman at home trial.mp4
The oncology hospital at home Health care utilization outcomes from the huntsman at home trial.pdf
The pediatric precision oncology study INFORM Clinical outcome and benefit for molecular subgroups.mp4
The pediatric precision oncology study INFORM Clinical outcome and benefit for molecular subgroups.pdf
The potential cost-effectiveness of a risk-based pancreatic cancer screening strategy in new-onset diabetes.mp4
The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy.mp4
The prevalence of HLA LOH across 10 cancer types in Chinese patients.mp4
The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.mp4
The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT).mp4
The role of tumor markers for relapse detection in central nervous system non-germinomatous germ cell tumors (CNS-NGGCT).pdf
The safety and efficacy of weekly paclitaxel and cisplatin chemotherapy for patients with ovarian cancer.mp4
The spatial localization of CD163+ tumor-associated macrophages predicts prognosis and response to therapy.mp4
The Times They Are a-Changin Evolving Trial Design for Early Breast Cancer.mp4
TheraP A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration.mp4
TheraP A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration.pdf
Therapeutic Approaches to Protein Degradation PROTACs and E3 Ligase Modulation.mp4
Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC).mp4
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.mp4
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) Impact of type of cancer therapy.mp4
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) Impact of type of cancer therapy.pdf
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST).mp4
Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST).pdf
Three versus six months of adjuvant chemotherapy for colorectal cancer A multi-country cost-effectiveness.mp4
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade.mp4
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade.pdf
Three-year follow-up of treatment-na‹ve and previously treated patients with Waldenstr”m macroglobulinemia (WM).mp4
TRACC Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer.mp4
Trainee and workforce diversity in hematology and oncology Ten years later what has changed.mp4
Trainee and workforce diversity in hematology and oncology Ten years later what has changed.pdf
Translational relevance of androgen receptor immunohistochemistry scoring systems for data harmonization.mp4
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable.mp4
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable.pdf
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patient.mp4
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC).mp4
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC).pdf
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction.mp4
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression NRG Oncology RTOG 1010.mp4
Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression NRG Oncology RTOG 1010.pdf
Treatment effects (TEs) of EGFR monoclonal antibodies (mAbs) in metastatic colorectal cancer (mCRC) patients (pts).mp4
Treatment intensity and risk of chronic health conditions and late mortality among long-term survivors of Wilms tumor.mp4
Trends in FDA cancer registration trial design over time, 1969-2020.mp4
Trial in progress A phase I II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects.mp4
Trial in progress A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy.mp4
Trial in progress A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination.mp4
Trial in progress a phase II, multicenter, single-arm study of zanubrutinib (BGB-3111) in patients with previously treated.mp4
Trial in progress Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.mp4
TRIDENT-1 A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid.mp4
TROPiCS-03 A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.mp4
U.S. trends and racial ethnic disparities in opioid access among patients with poor prognosis cancer at the end of life (EOL).mp4
U.S. trends and racial ethnic disparities in opioid access among patients with poor prognosis cancer at the end of life (EOL).pdf
Ultrasensitive multiplex detection of structural rearrangements in ALK, RET, ROS1 and PD-L1 using a comprehensive.mp4
Unanticipated Consequences Finding Germline Variants Through Somatic Profiling.mp4
Underdiagnosis and undertreament of modifiable cardiovascular risk factors A Childhood Cancer Survivor Study (CCSS) report.mp4
Underdiagnosis and undertreament of modifiable cardiovascular risk factors A Childhood Cancer Survivor Study (CCSS) report.pdf
Understanding and predicting fatigue, cardiovascular (CV) decline & events after breast cancer treatment (UPBEAT).mp4
UnTIL We Meet Again Immune Biomarkers in Early-Stage Disease.mp4
UnTIL We Meet Again Immune Biomarkers in Early-Stage Disease.pdf
Update of CARTITUDE-1 A phase Ib II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy.mp4
Update of CARTITUDE-1 A phase Ib II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy.pdf
Update on overall survival in COLUMBUS A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI).mp4
Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609).mp4
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.mp4
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.pdf
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus.mp4
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients.mp4
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients.pdf
Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+.mp4
Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C).mp4
Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy.mp4
Uptake of oophorectomy in women with findings on multigene panel testing.mp4
Uptake of oophorectomy in women with findings on multigene panel testing.pdf
Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC).mp4
Use of real-world data to understand barriers to interventional clinical trial enrollment in community oncology clinics (COC).mp4
Use of simulation for training family caregivers of patients receiving radiation therapy.mp4
Ushering Novel and Nontransplant Immune Therapies in Acute Leukemias.mp4
Ushering Novel and Nontransplant Immune Therapies in Acute Leukemias.pdf
Using Genomics to Select for Checkpoint Blockade.mp4
Using Genomics to Select for Checkpoint Blockade.pdf
Using machine learning to predict immunotherapy response in advanced melanoma.mp4
Using machine learning to predict immunotherapy response in advanced melanoma.pdf
Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.mp4
Uterine Serous Cancer Expanding Targets.pdf
Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP).mp4
Utility of circulating cell-free DNA (cfDNA) analysis in patients with carcinoma of unknown primary (CUP).pdf
Utilization of adjuvant chemotherapy in ‘ideal candidates’ with stage III colon cancer.mp4
Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA.mp4
Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA.pdf
Validation of an immunomodulatory gene signature algorithm to predict response to neoadjuvant immunochemotherapy.mp4
Validation of nomograms to predict non-sentinel lymph node metastasis after positive sentinel lymph node in breast.mp4
Validity of patient-reported outcomes to describe the symptom experience of patients enrolled on phase I clinical trials.mp4
VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments.mp4
Veliparib (V) monotherapy (monoTx) following combination therapy with V + carboplatin paclitaxel (CP) in patients.mp4
Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin paclitaxel (CP) in patients.mp4
Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy A cost-effectiveness analysis.mp4
Video conference intervention for distance caregivers (DCGs) of patients with cancer Improving psychological outcomes.mp4
Video vs in-person genetic counseling for men considering germline prostate cancer testing A patient-choice study.mp4
Vismodegib (V) for organ preservation for locally advanced (LA) orbital periocular basal cell carcinoma (BCC).mp4
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent progressive glioma.mp4
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent progressive glioma.pdf
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd).mp4
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd).pdf
Welcome and Introduction of Howard A. Burris, III, MD, FACP, FASCO.mp4
What’s Enough Regulatory Considerations.mp4
What’s Enough Regulatory Considerations.pdf
Who Goes First The Optimal Timing of Surgical Intervention in Operable Pancreas Cancer.mp4
Who Goes First The Optimal Timing of Surgical Intervention in Operable Pancreas Cancer.pdf
Whole transcriptome changes correlate to exceptional ovarian cancer responders A sub-analysis of a HIPEC Phase I trial.mp4
Window-of-opportunity trial of nivolumab with or without the IDO inhibitor BMS-986205 in patients with resectable.mp4
X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC).mp4
You Gotta Treat HER Right.mp4
You Gotta Treat HER Right.pdf

Reviews

There are no reviews yet.

Be the first to review “American Society of Clinical Oncology Virtual Scientific Program 2020”

Your email address will not be published. Required fields are marked *